-DOCSTART-	83

We	O
conclude	O
that	O
(	O
a	O
)	O
cyclophosphamide	B-Drug
is	O
a	O
human	B-ADE
teratogen	I-ADE
,	O
(	O
b	O
)	O
a	O
distinct	O
phenotype	O
exists	O
,	O
and	O
(	O
c	O
)	O
the	O
safety	O
of	O
CP	O
in	O
pregnancy	O
is	O
in	O
serious	O
question	O
.	O

-DOCSTART-	2566

Lethal	B-ADE
anuria	I-ADE
complicating	O
high	O
dose	O
ifosfamide	B-Drug
chemotherapy	O
in	O
a	O
breast	O
cancer	O
patient	O
with	O
an	O
impaired	O
renal	O
function	O
.	O

-DOCSTART-	475

A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	B-ADE
of	I-ADE
dermatitis	I-ADE
,	O
fever	B-ADE
,	O
lymphadenopathy	B-ADE
and	O
hepatitis	B-ADE
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Drug
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2399

Gemcitabine	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
is	O
usually	O
a	O
dramatic	O
condition	O
.	O

-DOCSTART-	2979

These	O
findings	O
support	O
previous	O
studies	O
that	O
showed	O
that	O
the	O
use	O
of	O
aspirin	B-Drug
during	O
the	O
antecedent	O
illness	O
may	O
be	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
RS	B-ADE
.	O

-DOCSTART-	1190

In	O
this	O
article	O
,	O
we	O
describe	O
another	O
case	O
of	O
subcutaneous	B-ADE
changes	I-ADE
following	O
repeated	O
glatiramer	B-Drug
acetate	I-Drug
injection	O
,	O
presented	O
as	O
localized	B-ADE
panniculitis	I-ADE
in	O
the	O
area	O
around	O
the	O
injection	O
sites	O
,	O
in	O
a	O
46-year	O
-	O
old	O
female	O
patient	O
who	O
was	O
treated	O
with	O
glatiramer	B-Drug
acetate	I-Drug
for	O
18	O
months	O
.	O

-DOCSTART-	3223

A	O
patient	O
with	O
alcoholic	O
cerebellar	O
degeneration	O
had	O
periodic	B-ADE
alternating	I-ADE
nystagmus	I-ADE
during	O
a	O
period	O
of	O
phenytoin	B-Drug
intoxication	O
.	O

-DOCSTART-	775

We	O
present	O
the	O
management	O
of	O
agranulocytosis	B-ADE
and	O
neutropenic	B-ADE
sepsis	I-ADE
secondary	O
to	O
carbimazole	B-Drug
with	O
recombinant	O
human	O
granulocyte	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
.	O

-DOCSTART-	1171

Peripheral	B-ADE
neuropathy	I-ADE
associated	O
with	O
capecitabine	B-Drug
.	O

-DOCSTART-	2917

Duodenal	B-ADE
ulceration	I-ADE
:	O
a	O
complication	O
of	O
tolazoline	B-Drug
therapy	O
.	O

-DOCSTART-	2985

According	O
to	O
the	O
literature	O
,	O
chlorambucil	B-Drug
central	B-ADE
nervous	I-ADE
toxicity	I-ADE
is	O
found	O
almost	O
exclusively	O
in	O
childhood	O
nephrotic	O
syndrome	O
.	O

-DOCSTART-	3625

Captopril	B-Drug
-	O
induced	O
bone	B-ADE
marrow	I-ADE
suppression	I-ADE
in	O
two	O
cardiac	O
patients	O
with	O
trisomy	O
21	O
.	O

-DOCSTART-	3857

Two	O
cases	O
of	O
mequitazine	B-Drug
-	O
induced	O
photosensitivity	B-ADE
reactions	I-ADE
.	O

-DOCSTART-	3432

Severe	O
bleomycin	B-Drug
lung	B-ADE
toxicity	I-ADE
:	O
reversal	O
with	O
high	O
dose	O
corticosteroids	O
.	O

-DOCSTART-	316

Poorly	O
controlled	O
hypertension	O
in	O
a	O
painter	O
with	O
chronic	O
lead	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	3163

Additive	B-ADE
pulmonary	I-ADE
toxicity	I-ADE
with	O
melphalan	B-Drug
and	O
busulfan	B-Drug
therapy	O
.	O

-DOCSTART-	3251

A	O
55-yr	O
-	O
old	O
man	O
developed	O
prolonged	B-ADE
jaundice	I-ADE
and	O
sicca	B-ADE
complex	I-ADE
after	O
a	O
course	O
of	O
thiabendazole	B-Drug
therapy	O
.	O

-DOCSTART-	1919

Rapid	O
onset	O
of	O
muscle	B-ADE
weakness	I-ADE
(	O
rhabdomyolysis	B-ADE
)	O
associated	O
with	O
the	O
combined	O
use	O
of	O
simvastatin	B-Drug
and	O
colchicine	B-Drug
.	O

-DOCSTART-	2838

Extensive	O
immunological	O
investigations	O
were	O
performed	O
in	O
a	O
patient	O
with	O
definite	O
seronegative	O
rheumatoid	O
arthritis	O
who	O
developed	O
hypogammaglobulinemia	B-ADE
in	O
the	O
course	O
of	O
gold	B-Drug
therapy	O
.	O

-DOCSTART-	4130

In	O
case	O
1	O
,	O
a	O
total	O
daily	O
dose	O
of	O
25	O
mg	O
sertraline	B-Drug
,	O
with	O
nondetectable	O
sertraline	B-Drug
and	O
desmethylsertraline	B-Drug
blood	O
levels	O
,	O
resulted	O
in	O
a	O
doubling	B-ADE
of	I-ADE
the	I-ADE
lamotrigine	I-ADE
blood	I-ADE
level	I-ADE
with	O
symptoms	B-ADE
of	I-ADE
toxicity	I-ADE
.	O

-DOCSTART-	598

Metamizole	B-Drug
,	O
a	O
nonsteroidal	O
antiinflammatory	O
agent	O
,	O
is	O
prohibited	O
in	O
the	O
United	O
States	O
because	O
of	O
the	O
risk	O
of	O
agranulocytosis	B-ADE
but	O
is	O
widely	O
used	O
in	O
Mexico	O
and	O
other	O
countries	O
.	O

-DOCSTART-	2527

Our	O
patient	O
had	O
headache	B-ADE
,	O
mild	B-ADE
fever	I-ADE
,	O
nausea	B-ADE
,	O
vomiting	B-ADE
,	O
rash	B-ADE
,	O
and	O
eosinophilia	B-ADE
after	O
3	O
weeks	O
of	O
disulfiram	B-Drug
therapy	O
.	O

-DOCSTART-	1607

An	O
unusual	O
presentation	O
of	O
spontaneous	O
sub	B-ADE
-	I-ADE
conjunctival	I-ADE
haematoma	I-ADE
in	O
a	O
patient	O
receiving	O
warfarin	B-Drug
.	O

-DOCSTART-	49

It	O
carries	O
a	O
well	O
-	O
known	O
risk	O
of	O
neutropenia	B-ADE
and	O
agranulocytosis	B-ADE
,	O
which	O
necessitates	O
the	O
immediate	O
discontinuation	O
of	O
clozapine	B-Drug
.	O

-DOCSTART-	2568

Ciprofloxacin	B-Drug
is	O
one	O
drug	O
that	O
has	O
been	O
reported	O
to	O
cause	O
interstitial	B-ADE
nephritis	I-ADE
.	O

-DOCSTART-	908

Although	O
both	O
the	O
spontaneous	O
occurrence	O
of	O
SLE	B-ADE
and	O
the	O
psychosis	O
as	O
a	O
sign	O
of	O
CNS	O
involvement	O
of	O
SLE	B-ADE
can	O
not	O
be	O
excluded	O
,	O
SLE	B-ADE
could	O
be	O
considered	O
as	O
an	O
adverse	O
effect	O
of	O
carbamazepine	B-Drug
.	O

-DOCSTART-	3931

A	O
17-year	O
-	O
old	O
female	O
patient	O
who	O
had	O
been	O
taking	O
oral	O
minocycline	B-Drug
(	O
50	O
mg	O
twice	O
daily	O
)	O
for	O
3	O
weeks	O
for	O
acne	O
developed	O
an	O
eruption	B-ADE
that	O
progressed	O
to	O
an	O
exfoliative	B-ADE
dermatitis	I-ADE
.	O

-DOCSTART-	1638

Though	O
they	O
are	O
generally	O
considered	O
safe	O
,	O
there	O
have	O
been	O
a	O
few	O
reports	O
of	O
myocardial	B-ADE
infarction	I-ADE
and	O
stroke	B-ADE
associated	O
with	O
triptan	B-Drug
use	O
.	O

-DOCSTART-	2623

A	O
35-year	O
-	O
old	O
female	O
with	O
borderline	O
lepromatous	O
(	O
BL	O
)	O
leprosy	O
who	O
suffered	O
from	O
dapsone	B-Drug
-	O
induced	O
erythroderma	B-ADE
is	O
reported	O
.	O

-DOCSTART-	9

We	O
describe	O
the	O
side	O
effects	O
of	O
5-FU	B-Drug
in	O
a	O
colon	O
cancer	O
patient	O
who	O
suffered	O
severe	B-ADE
mucositis	I-ADE
,	O
desquamating	O
dermatitis	O
,	O
prolonged	B-ADE
myelosuppression	I-ADE
,	O
and	O
neurologic	B-ADE
toxicity	I-ADE
that	O
required	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

-DOCSTART-	3343

Two	O
patients	O
with	O
rheumatoid	O
arthritis	O
developed	O
evidence	O
of	O
hepatotoxicity	B-ADE
while	O
receiving	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
.	O

-DOCSTART-	2823

Gold	B-Drug
-	O
induced	O
pneumonitis	B-ADE
is	O
a	O
rare	O
complication	O
of	O
gold	O
salt	O
therapy	O
.	O

-DOCSTART-	665

Gemcitabine	B-Drug
-	O
associated	O
hemolytic	B-ADE
-	I-ADE
uremic	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	4244

Massive	B-ADE
subfascial	I-ADE
hematoma	I-ADE
after	O
alteplase	B-Drug
therapy	O
for	O
acute	O
myocardial	O
infarction	O
.	O

-DOCSTART-	535

She	O
was	O
admitted	O
following	O
a	O
fall	O
and	O
,	O
after	O
being	O
given	O
metoclopramide	B-Drug
,	O
developed	O
movement	B-ADE
disorder	I-ADE
and	O
a	O
period	O
of	O
unresponsiveness	B-ADE
.	O

-DOCSTART-	2427

PURPOSE	O
:	O
The	O
case	O
of	O
a	O
patient	O
who	O
developed	O
aseptic	B-ADE
meningitis	I-ADE
,	O
hemolytic	B-ADE
anemia	I-ADE
,	O
hepatitis	B-ADE
,	O
and	O
orthostatic	B-ADE
hypotension	I-ADE
simultaneously	O
during	O
treatment	O
with	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
is	O
described	O
.	O

-DOCSTART-	574

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
that	O
demonstrates	O
histological	B-ADE
abnormalities	I-ADE
of	I-ADE
the	I-ADE
glomerulus	I-ADE
associated	O
with	O
postoperative	O
IFN	B-Drug
-	I-Drug
beta	I-Drug
therapy	O
for	O
the	O
malignant	O
melanoma	O
.	O

-DOCSTART-	1583

Several	O
hypersensitivity	B-ADE
reactions	O
to	O
cloxacillin	B-Drug
have	O
been	O
reported	O
,	O
although	O
IgE	B-ADE
-	I-ADE
mediated	I-ADE
allergic	I-ADE
reactions	I-ADE
to	O
the	O
drug	O
are	O
rare	O
and	O
there	O
is	O
little	O
information	O
about	O
possible	O
tolerance	O
to	O
other	O
semisynthetic	O
penicillins	O
or	O
cephalosporins	O
in	O
patients	O
with	O
cloxacillin	O
allergy	O
.	O

-DOCSTART-	3883

OBJECTIVE	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
may	O
mediate	O
the	O
loss	O
and	O
the	O
dedifferentiation	O
of	O
subcutaneous	O
fat	O
tissue	O
in	O
the	O
insulin	B-Drug
-	O
induced	O
lipoatrophies	B-ADE
of	O
a	O
diabetic	O
patient	O
who	O
presented	O
extensive	O
lesions	O
.	O

-DOCSTART-	2279

The	O
most	O
common	O
complication	O
of	O
warfarin	B-Drug
use	O
is	O
adverse	O
bleeding	B-ADE
.	O

-DOCSTART-	1008

It	O
was	O
highly	O
suspected	O
that	O
finasteride	B-Drug
was	O
associated	O
with	O
the	O
anterior	B-ADE
subcapsular	I-ADE
opacity	I-ADE
on	I-ADE
the	I-ADE
lens	I-ADE
,	O
and	O
the	O
patient	O
therefore	O
discontinued	O
use	O
of	O
finasteride	B-Drug
.	O

-DOCSTART-	512

Pulmonary	B-ADE
toxicity	I-ADE
with	O
mefloquine	B-Drug
.	O

-DOCSTART-	1737

Methylphenidate	B-Drug
(	O
Ritalin	B-Drug
)	O
-	O
associated	O
cataract	B-ADE
and	O
glaucoma	B-ADE
.	O

-DOCSTART-	3389

In	O
the	O
absence	O
of	O
mucositis	O
or	O
diarrhea	O
,	O
severe	B-ADE
dermatologic	I-ADE
toxicity	I-ADE
following	O
a	O
single	O
low	O
dose	O
of	O
the	O
drug	O
suggests	O
an	O
'	O
allergic	O
'	O
or	O
acute	B-ADE
hypersensitivity	I-ADE
reaction	I-ADE
to	O
MTX	B-Drug
in	O
this	O
patient	O
.	O

-DOCSTART-	2998

A	O
literature	O
review	O
revealed	O
83	O
other	O
reported	O
cases	O
of	O
rifampicin	B-Drug
-	O
induced	O
renal	B-ADE
insufficiency	I-ADE
.	O

-DOCSTART-	420

We	O
report	O
the	O
occurrence	O
of	O
spontaneous	O
intracranial	B-ADE
bleeding	I-ADE
in	O
an	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
infected	O
adolescent	O
with	O
hemophilia	O
A	O
who	O
was	O
receiving	O
amprenavir	B-Drug
(	O
APV	O
)	O
.	O

-DOCSTART-	1370

The	O
multiple	B-ADE
comedones	I-ADE
and	O
ruptured	B-ADE
epidermoid	I-ADE
cysts	I-ADE
are	O
newly	O
reported	O
adverse	O
effects	O
of	O
imiquimod	B-Drug
therapy	O
.	O

-DOCSTART-	2982

Amiodarone	B-Drug
-	O
induced	O
dysthyroidism	B-ADE
.	O

-DOCSTART-	1153

Multiple	O
mechanisms	O
for	O
ciprofloxacin	B-Drug
-	O
induced	O
nephrotoxicity	B-ADE
have	O
been	O
proposed	O
.	O

-DOCSTART-	2086

Here	O
,	O
we	O
describe	O
levofloxacin	B-Drug
-	O
induced	O
delirium	B-ADE
with	I-ADE
psychotic	I-ADE
features	I-ADE
in	O
a	O
relatively	O
young	O
,	O
otherwise	O
healthy	O
female	O
.	O

-DOCSTART-	1123

Possible	O
induction	O
of	O
diabetes	B-ADE
by	O
treatment	O
of	O
hypertension	O
with	O
indapamide	B-Drug
(	O
with	O
four	O
case	O
reports	O
)	O
.	O

-DOCSTART-	2059

There	O
are	O
major	O
side	O
effects	O
of	O
anastrozole	B-Drug
including	O
decrease	B-ADE
in	I-ADE
both	I-ADE
lumbar	I-ADE
spine	I-ADE
and	O
total	O
hip	O
bone	O
mineral	O
density	O
,	O
increase	B-ADE
in	I-ADE
the	I-ADE
incidence	I-ADE
of	I-ADE
all	I-ADE
bone	I-ADE
fractures	I-ADE
(	O
especially	O
fractures	O
of	O
spine	O
,	O
hip	O
and	O
wrist	O
)	O
,	O
joint	B-ADE
disorders	I-ADE
and	O
increase	B-ADE
in	I-ADE
the	I-ADE
cholesterol	I-ADE
level	I-ADE
.	O

-DOCSTART-	2118

CASE	O
SUMMARY	O
:	O
An	O
80-year	O
-	O
old	O
white	O
female	O
,	O
followed	O
up	O
at	O
the	O
Memory	O
Clinic	O
for	O
mild	B-ADE
cognitive	I-ADE
impairment	I-ADE
,	O
had	O
been	O
taking	O
propafenone	B-Drug
900	O
mg	O
/	O
d	O
for	O
>	O
10	O
years	O
for	O
paroxysmal	O
atrial	O
fibrillation	O
without	O
adverse	O
effects	O
.	O

-DOCSTART-	1201

We	O
present	O
a	O
20-year	O
-	O
old	O
woman	O
with	O
Basedow	O
-	O
Graves	O
'	O
disease	O
who	O
developed	O
PTU	B-Drug
-	O
induced	O
fulminant	B-ADE
hepatitis	I-ADE
,	O
which	O
progressed	O
to	O
acute	O
hepatic	O
failure	O
with	O
grade	O
III	O
hepatic	O
encephalopathy	O
.	O

-DOCSTART-	1333

The	O
knowledge	O
concerning	O
VGB	B-Drug
-	O
associated	O
visual	B-ADE
dysfunction	I-ADE
in	O
pediatric	O
patients	O
,	O
particularly	O
in	O
those	O
who	O
have	O
been	O
exposed	O
to	O
VGB	O
in	O
utero	O
is	O
limited	O
.	O

-DOCSTART-	3062

In	O
addition	O
,	O
loading	O
with	O
one	O
low	O
oral	O
dose	O
of	O
serine	B-Drug
produced	O
psychotic	B-ADE
symptoms	I-ADE
5	O
h	O
later	O
which	O
lasted	O
3	O
-	O
6	O
h	O
.	O

-DOCSTART-	1043

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
ciprofloxacin	B-Drug
-	O
induced	O
psychosis	B-ADE
and	O
to	O
discuss	O
occurrence	O
rates	O
,	O
risk	O
factors	O
,	O
possible	O
etiologies	O
,	O
preventive	O
measures	O
,	O
and	O
treatment	O
courses	O
for	O
this	O
adverse	O
reaction	O
.	O

-DOCSTART-	4228

Pamidronate	O
therapy	O
should	O
be	O
considered	O
in	O
patients	O
with	O
hypercalcemia	B-ADE
secondary	O
to	O
acute	B-ADE
vitamin	I-ADE
D	I-ADE
poisoning	I-ADE
.	O

-DOCSTART-	1413

One	O
of	O
the	O
side	O
-	O
effects	O
of	O
intravitreal	O
triamcinolone	B-Drug
is	O
the	O
development	O
of	O
cataract	B-ADE
,	O
and	O
it	O
is	O
known	O
that	O
cataract	O
extraction	O
can	O
exacerbate	O
macular	O
degeneration	O
.	O

-DOCSTART-	4075

PURPOSE	O
:	O
To	O
present	O
a	O
case	O
of	O
respiratory	B-ADE
depression	I-ADE
following	O
the	O
administration	O
of	O
nebulised	O
morphine	B-Drug
.	O

-DOCSTART-	1344

Cutaneous	B-ADE
necrosis	I-ADE
after	O
injection	O
of	O
polyethylene	O
glycol	O
-	O
modified	O
interferon	B-Drug
alfa	I-Drug
.	O

-DOCSTART-	3888

Well	O
-	O
known	O
signs	O
of	O
methotrexate	B-Drug
toxicity	I-ADE
include	O
bone	B-ADE
marrow	I-ADE
suppression	I-ADE
and	O
oral	B-ADE
and	I-ADE
gastrointestinal	I-ADE
ulceration	I-ADE
.	O

-DOCSTART-	1861

Fulminant	O
metoclopramide	B-Drug
induced	O
neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
rapidly	O
responsive	O
to	O
intravenous	O
dantrolene	O
.	O

-DOCSTART-	4058

A	O
25-year	O
-	O
old	O
woman	O
sought	O
medical	O
attention	O
because	O
of	O
iliocaval	O
manifestations	O
of	O
retroperitoneal	B-ADE
fibrosis	I-ADE
while	O
she	O
was	O
taking	O
methysergide	B-Drug
.	O

-DOCSTART-	1672

Bronchiolitis	B-ADE
obliterans	I-ADE
with	I-ADE
organizing	I-ADE
pneumonia	I-ADE
after	O
rituximab	B-Drug
therapy	O
for	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
.	O

-DOCSTART-	3861

Potential	O
causes	O
of	O
methamphetamine	B-Drug
-	O
related	O
keratitis	B-ADE
can	O
be	O
divided	O
into	O
four	O
categories	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effects	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	B-ADE
effects	I-ADE
of	O
diluting	O
or	O
"	O
cutting	O
"	O
agents	O
such	O
as	O
lidocaine	B-Drug
and	O
quinine	B-Drug
;	O
(	O
c	O
)	O
effects	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture	O
-	O
related	O
effects	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminants	O
in	O
the	O
final	O
product	O
.	O

-DOCSTART-	1460

We	O
report	O
a	O
case	O
of	O
senna	B-Drug
-	O
induced	O
cholestatic	B-ADE
hepatitis	I-ADE
which	O
was	O
not	O
diagnosed	O
at	O
presentation	O
.	O

-DOCSTART-	1395

Primary	O
CNS	B-ADE
lymphoma	I-ADE
complicating	O
treatment	O
of	O
myasthenia	O
gravis	O
with	O
mycophenolate	B-Drug
mofetil	I-Drug
.	O

-DOCSTART-	1021

Cutaneous	B-ADE
vasculitis	I-ADE
secondary	O
to	O
ramipril	B-Drug
.	O

-DOCSTART-	1679

We	O
report	O
a	O
case	O
of	O
successful	O
surgical	O
management	O
of	O
arterial	B-ADE
thrombosis	I-ADE
after	O
percutaneous	O
thrombin	B-Drug
injection	O
of	O
a	O
femoral	O
artery	O
pseudoaneurysm	O
in	O
a	O
69-year	O
-	O
old	O
woman	O
.	O

-DOCSTART-	2354

Acute	B-ADE
vision	I-ADE
loss	I-ADE
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
(	O
avastin	B-Drug
)	O
associated	O
with	O
ocular	B-ADE
ischemic	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	3892

Hypoxemia	O
improved	O
during	O
continuous	O
tolazoline	B-Drug
infusion	O
,	O
but	O
gastrointestinal	B-ADE
bleeding	I-ADE
occurred	O
.	O

-DOCSTART-	87

CONCLUSIONS	O
:	O
This	O
case	O
suggests	O
that	O
losartan	B-Drug
can	O
induce	O
late	O
-	O
onset	O
angioedema	B-ADE
in	O
patients	O
with	O
normal	O
renal	O
function	O
and	O
that	O
the	O
reaction	O
can	O
recur	O
after	O
initial	O
resolution	O
of	O
the	O
symptoms	O
.	O

-DOCSTART-	2664

We	O
present	O
the	O
first	O
case	O
of	O
WES	B-ADE
in	O
an	O
infant	O
born	O
to	O
a	O
mother	O
taking	O
haloperidol	B-Drug
during	O
her	O
pregnancy	O
.	O

-DOCSTART-	3868

Studies	O
performed	O
10	O
years	O
ago	O
on	O
25	O
patients	O
with	O
MTX	B-Drug
-	O
induced	O
liver	B-ADE
cirrhosis	I-ADE
indicated	O
that	O
this	O
type	O
of	O
cirrhosis	B-ADE
was	O
not	O
of	O
an	O
aggressive	O
nature	O
.	O

-DOCSTART-	2185

A	O
case	O
of	O
congestive	B-ADE
heart	I-ADE
failure	I-ADE
in	O
a	O
child	O
with	O
Wilms	O
'	O
tumor	O
treated	O
Adriamycin	B-Drug
is	O
presented	O
and	O
discussed	O
.	O

-DOCSTART-	4179

A	O
47	O
year	O
-	O
old	O
woman	O
who	O
had	O
a	O
4-year	O
history	O
of	O
intramuscular	O
pentazocine	B-Drug
injections	O
in	O
the	O
lower	O
extremities	O
,	O
developed	O
gradual	B-ADE
stiffness	I-ADE
and	O
weakness	B-ADE
of	I-ADE
the	I-ADE
lower	I-ADE
extremities	I-ADE
.	O

-DOCSTART-	3202

Gynecomastia	B-ADE
associated	O
with	O
theophylline	B-Drug
.	O

-DOCSTART-	3010

Conversely	O
,	O
diffuse	B-ADE
interstitial	I-ADE
pulmonary	I-ADE
fibrosis	I-ADE
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
patients	O
receiving	O
methotrexate	B-Drug
who	O
develop	O
bilateral	B-ADE
pulmonary	I-ADE
infiltrates	I-ADE
seen	O
on	O
chest	O
roentgenograms	O
.	O

-DOCSTART-	3761

Captopril	B-Drug
is	O
known	O
to	O
be	O
associated	O
with	O
dermatologic	B-ADE
,	I-ADE
hematologic	I-ADE
,	I-ADE
and	I-ADE
pulmonary	I-ADE
adverse	I-ADE
effects	I-ADE
.	O

-DOCSTART-	2256

We	O
conclude	O
that	O
while	O
thrombocytopenia	B-ADE
and	O
schistocytosis	B-ADE
can	O
be	O
seen	O
in	O
quinine	B-Drug
-	O
associated	O
TTP	B-ADE
/	I-ADE
HUS	I-ADE
,	O
the	O
pathophysiology	O
seems	O
to	O
be	O
distinct	O
from	O
that	O
seen	O
in	O
most	O
cases	O
of	O
idiopathic	O
TTP	O
(	O
i.e.	O
,	O
severely	O
decreased	O
ADAMTS13	O
with	O
an	O
inhibitor	O
)	O
.	O

-DOCSTART-	978

2-CdA	B-Drug
typically	O
causes	O
a	O
long	O
-	O
lasting	O
state	O
of	O
immunodeficiency	B-ADE
and	O
the	O
profound	O
influence	O
of	O
this	O
drug	O
on	O
the	O
immune	O
system	O
has	O
raised	O
questions	O
concerning	O
the	O
emergence	O
of	O
secondary	B-ADE
neoplasms	I-ADE
after	O
its	O
use	O
.	O

-DOCSTART-	4196

Tubulointerstitial	B-ADE
nephritis	I-ADE
induced	O
by	O
the	O
leukotriene	O
receptor	O
antagonist	O
pranlukast	B-Drug
.	O

-DOCSTART-	3916

Large	B-ADE
cerebral	I-ADE
infarction	I-ADE
during	O
praziquantel	B-Drug
therapy	O
in	O
neurocysticercosis	O
.	O

-DOCSTART-	3579

Significant	O
clinical	O
improvement	O
of	O
the	O
porphyria	B-ADE
followed	O
withdrawal	O
of	O
the	O
diphenylhydantoin	B-Drug
.	O

-DOCSTART-	3130

The	O
temporal	O
sequence	O
of	O
the	O
respiratory	B-ADE
insufficiency	I-ADE
and	O
the	O
histopathology	O
,	O
when	O
compared	O
to	O
the	O
previous	O
examples	O
in	O
the	O
literature	O
,	O
suggest	O
that	O
cyclophosphamide	B-Drug
was	O
aetiologically	O
responsible	O
for	O
the	O
lung	B-ADE
disease	I-ADE
.	O

-DOCSTART-	2448

Transient	O
trazodone	B-Drug
-	O
induced	O
hypomanic	B-ADE
symptoms	I-ADE
occurred	O
in	O
three	O
depressed	O
patients	O
.	O

-DOCSTART-	3456

The	O
dose	O
-	O
limiting	O
toxicity	O
of	O
KW-2149	B-Drug
is	O
pulmonary	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	592

CONCLUSIONS	O
:	O
Priapism	B-ADE
is	O
an	O
uncommon	O
but	O
potentially	O
serious	O
adverse	O
effect	O
of	O
zuclopenthixol	B-Drug
that	O
practitioners	O
,	O
as	O
with	O
many	O
other	O
antipsychotics	O
,	O
should	O
be	O
aware	O
of	O
.	O

-DOCSTART-	735

Successful	O
desensitization	O
to	O
high	O
-	O
dose	O
methotrexate	B-Drug
after	O
systemic	B-ADE
anaphylaxis	I-ADE
.	O

-DOCSTART-	1557

Hence	O
,	O
hyperthyroidism	B-ADE
induced	O
by	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
could	O
correspond	O
to	O
the	O
first	O
phase	O
of	O
silent	O
thyroiditis	O
,	O
to	O
Graves	O
'	O
disease	O
or	O
to	O
the	O
succession	O
of	O
both	O
.	O

-DOCSTART-	2341

He	O
had	O
also	O
developed	O
elevated	B-ADE
serum	I-ADE
ammonia	I-ADE
levels	I-ADE
while	O
on	O
valproic	B-Drug
acid	I-Drug
.	O

-DOCSTART-	1755

Heparin	B-Drug
-	O
associated	O
thrombocytopenia	B-ADE
and	O
thrombosis	B-ADE
is	O
a	O
severe	O
complication	O
of	O
systemic	O
heparin	B-Drug
therapy	O
.	O

-DOCSTART-	1724

Tacrolimus	B-Drug
-	O
induced	O
HUS	B-ADE
:	O
an	O
unusual	O
cause	O
of	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
in	O
nephrotic	O
syndrome	O
.	O

-DOCSTART-	1425

The	O
major	O
side	O
effect	O
of	O
infliximab	B-Drug
is	O
infection	B-ADE
.	O

-DOCSTART-	709

Clinical	B-ADE
,	I-ADE
spectroscopic	I-ADE
,	I-ADE
and	I-ADE
imaging	I-ADE
abnormalities	I-ADE
resolved	O
with	O
discontinuation	O
of	O
metronidazole	B-Drug
.	O

-DOCSTART-	910

SLE	B-ADE
receded	O
after	O
withdrawal	O
of	O
carbamazepine	B-Drug
and	O
treatment	O
with	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

-DOCSTART-	889

Heparin	B-Drug
-	O
associated	O
thrombocytopenia	B-ADE
:	O
successful	O
therapy	O
with	O
the	O
heparinoid	O
Org	O
10172	O
in	O
a	O
patient	O
showing	O
cross	O
-	O
reaction	O
to	O
LMW	O
heparins	O
.	O

-DOCSTART-	3153

Alternating	B-ADE
sinus	I-ADE
rhythm	I-ADE
and	O
intermittent	B-ADE
sinoatrial	I-ADE
block	I-ADE
induced	O
by	O
propranolol	B-Drug
.	O

-DOCSTART-	1603

PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
traumatic	B-ADE
flap	I-ADE
dehiscence	I-ADE
and	O
Enterobacter	B-ADE
keratitis	I-ADE
34	O
months	O
after	O
LASIK	B-Drug
.	O

-DOCSTART-	3307

A	O
67-year	O
-	O
old	O
man	O
developed	O
diarrhea	B-ADE
shortly	O
after	O
a	O
10-day	O
course	O
of	O
oral	O
ampicillin	B-Drug
.	O

-DOCSTART-	1051

However	O
here	O
we	O
reported	O
two	O
patients	O
,	O
presenting	O
with	O
PD	B-ADE
during	O
high	O
dose	O
colchicine	B-Drug
treatment	O
for	O
familiar	O
mediterranean	O
fever	O
(	O
FMF	O
)	O
.	O

-DOCSTART-	2027

A	O
51-year	O
-	O
old	O
man	O
developed	O
type	B-ADE
1	I-ADE
diabetes	I-ADE
mellitus	I-ADE
following	O
24	O
weeks	O
of	O
treatment	O
with	O
recombinant	O
alpha-2b	B-Drug
peginterferon	I-Drug
plus	O
ribavirin	B-Drug
for	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	1678

Native	O
arterial	B-ADE
thrombosis	I-ADE
,	O
though	O
recognized	O
as	O
a	O
severe	O
complication	O
of	O
thrombin	B-Drug
injection	O
,	O
has	O
not	O
been	O
well	O
described	O
in	O
the	O
literature	O
.	O

-DOCSTART-	231

Recurrent	O
septicemia	B-ADE
with	O
lethal	B-ADE
outcome	O
during	O
and	O
after	O
cyclosporine	B-Drug
therapy	O
in	O
severe	O
ulcerative	O
colitis	O
.	O

-DOCSTART-	1161

Despite	O
the	O
low	O
dosage	O
of	O
warfarin	B-Drug
,	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
was	O
markedly	O
elevated	O
from	O
1.15	O
to	O
11.28	O
for	O
only	O
4	O
days	O
,	O
and	O
bleeding	B-ADE
symptoms	I-ADE
concurrently	O
developed	O
.	O

-DOCSTART-	1693

Nephrotic	B-ADE
syndrome	I-ADE
associated	O
with	O
interferon	B-Drug
-	I-Drug
beta-1b	I-Drug
therapy	O
for	O
multiple	O
sclerosis	O
.	O

-DOCSTART-	3042

Fatal	B-ADE
acute	I-ADE
tubular	I-ADE
necrosis	I-ADE
occurred	O
in	O
1	O
patient	O
in	O
whom	O
intravesical	O
formalin	B-Drug
was	O
used	O
to	O
control	O
massive	O
persistent	O
hemorrhage	O
from	O
radiation	O
cystitis	O
.	O

-DOCSTART-	416

Digestive	B-ADE
hemorrhage	I-ADE
caused	O
by	O
a	O
Meckel	O
's	O
diverticulum	O
in	O
a	O
metformin	B-Drug
-	O
treated	O
patient	O
:	O
is	O
there	O
any	O
connection	O
?	O

-DOCSTART-	4122

Increased	B-ADE
ocular	I-ADE
pressure	I-ADE
in	O
two	O
patients	O
with	O
narrow	O
angle	O
glaucoma	O
treated	O
with	O
venlafaxine	B-Drug
.	O

-DOCSTART-	3580

A	O
53-year	O
-	O
old	O
male	O
,	O
without	O
any	O
prior	O
history	O
of	O
psychosis	O
,	O
developed	O
schizophrenia	B-ADE
4	O
days	O
after	O
starting	O
low	O
-	O
dose	O
bromocriptine	B-Drug
therapy	O
for	O
a	O
macroprolactinoma	O
.	O

-DOCSTART-	1513

We	O
reviewed	O
the	O
literature	O
in	O
an	O
attempt	O
to	O
characterize	O
the	O
pattern	O
and	O
predictors	O
of	O
TMP	B-Drug
/	O
SMX	B-Drug
-	O
induced	O
aseptic	B-ADE
meningitis	I-ADE
.	O

-DOCSTART-	1467

CASE	O
SUMMARY	O
:	O
A	O
45-year	O
-	O
old	O
HIV	O
-	O
positive	O
man	O
(	O
CD4	O
+	O
count	O
450	O
cells	O
/	O
mm(3	O
)	O
and	O
history	O
of	O
AIDS	O
-	O
defining	O
illness	O
)	O
presented	O
with	O
JHR	B-ADE
after	O
an	O
initial	O
intravenous	O
dose	O
of	O
penicillin	B-Drug
G	I-Drug
for	O
presumed	O
neurosyphilis	O
.	O

-DOCSTART-	62

A	O
5-month	O
-	O
old	O
infant	O
became	O
lethargic	B-ADE
and	O
poorly	B-ADE
responsive	I-ADE
after	O
receiving	O
1	O
drop	O
of	O
brimonidine	B-Drug
in	O
each	O
eye	O
.	O

-DOCSTART-	646

Drug	O
-	O
induced	O
mammary	B-ADE
hyperplasias	I-ADE
have	O
been	O
reported	O
as	O
rare	O
complications	O
of	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
and	O
Neothetazone	B-Drug
.	O

-DOCSTART-	1235

Neuropathy	B-ADE
is	O
a	O
significant	O
side	O
effect	O
of	O
thalidomide	B-Drug
therapy	O
,	O
which	O
may	O
limit	O
its	O
clinical	O
use	O
.	O

-DOCSTART-	3165

After	O
taking	O
cholestyramine	B-Drug
II	I-Drug
sachets	O
twice	O
daily	O
for	O
two	O
months	O
she	O
presented	O
with	O
lethargy	B-ADE
,	O
confusion	B-ADE
and	O
drowsiness	B-ADE
.	O

-DOCSTART-	2247

Hypoglycemia	B-ADE
can	O
be	O
a	O
serious	O
side	O
effect	O
of	O
etanercept	B-Drug
in	O
patients	O
already	O
on	O
antidiabetic	O
medications	O
known	O
to	O
cause	O
hypoglycemia	B-ADE
,	O
such	O
as	O
sulfonylureas	B-Drug
,	O
meglitinides	B-Drug
,	O
and	O
insulin	B-Drug
.	O

-DOCSTART-	1630

The	O
hepatic	B-ADE
enzyme	I-ADE
disturbances	I-ADE
normalized	O
after	O
discontinuation	O
of	O
pegvisomant	B-Drug
.	O

-DOCSTART-	2194

Despite	O
these	O
antithrombotic	O
effects	O
,	O
the	O
patient	O
developed	O
repeated	O
venous	B-ADE
thromboembolism	I-ADE
during	O
treatment	O
with	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	B-Drug
.	O

-DOCSTART-	1990

According	O
to	O
the	O
Naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
,	O
the	O
likelihood	O
that	O
temozolomide	B-Drug
was	O
responsible	O
for	O
the	O
adverse	O
drug	O
reaction	O
of	O
fever	B-ADE
was	O
probable	O
(	O
score	O
of	O
6	O
)	O
.	O

-DOCSTART-	2005

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
who	O
developed	O
photo	B-ADE
-	I-ADE
onycholysis	I-ADE
on	O
multiple	O
nails	O
after	O
uptake	O
of	O
olanzapine	B-Drug
.	O

-DOCSTART-	2447

Spectral	O
-	O
domain	O
optical	O
coherence	O
tomography	O
and	O
adaptive	O
optics	O
may	O
detect	O
hydroxychloroquine	B-Drug
retinal	B-ADE
toxicity	I-ADE
before	O
symptomatic	O
vision	O
loss	O
.	O

-DOCSTART-	1076

The	O
day	O
after	O
methotrexate	B-Drug
administration	O
,	O
the	O
patient	O
complained	O
of	O
severe	B-ADE
back	I-ADE
pain	I-ADE
and	O
urinary	B-ADE
retention	I-ADE
.	O

-DOCSTART-	1168

Neurologic	B-ADE
symptoms	I-ADE
resolved	O
after	O
stopping	O
CAP	B-Drug
for	O
4	O
weeks	O
in	O
Patient	O
A	O
,	O
with	O
no	O
recurrence	O
after	O
reinitiating	O
CAP	B-Drug
alone	O
at	O
2000	O
mg	O
/	O
m2	O
.	O

-DOCSTART-	2365

Reversible	O
methotrexate	B-Drug
-	O
associated	O
lymphoproliferative	B-ADE
disorder	I-ADE
resembling	O
advanced	O
gastric	O
cancer	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	359

We	O
report	O
a	O
patient	O
with	O
advanced	O
colonic	O
carcinoma	O
who	O
was	O
treated	O
with	O
concomitant	O
chemoirradiation	O
with	O
oxaliplatin	B-Drug
and	O
developed	O
a	O
peculiar	O
dermnatitis	B-ADE
in	O
the	O
irradiated	O
field	O
after	O
being	O
exposed	O
to	O
subsequent	O
chemotherapy	O
with	O
oxaliplatin	O
.	O

-DOCSTART-	1544

Disseminated	B-ADE
tuberculous	I-ADE
lesions	I-ADE
post	O
intravesical	O
BCG	B-Drug
therapy	O
are	O
rare	O
but	O
need	O
to	O
be	O
identified	O
and	O
treated	O
quickly	O
.	O

-DOCSTART-	2746

Three	O
patients	O
,	O
in	O
whom	O
tumour	O
overkill	O
by	O
cytotoxic	O
treatment	O
,	O
including	O
high	O
dose	O
methotrexate	B-Drug
with	O
folinic	B-Drug
acid	I-Drug
rescue	O
,	O
resulted	O
in	O
the	O
'	O
phosphate	B-ADE
shower	I-ADE
syndrome	I-ADE
'	O
(	O
hyper	B-ADE
-	I-ADE
uricaemia	I-ADE
,	O
hyperkalaemia	B-ADE
and	O
hyperphosphataemia	B-ADE
with	O
hypocalcaemia	B-ADE
and	O
tetany	B-ADE
,	O
with	O
metabolic	B-ADE
acidosis	I-ADE
and	O
acute	B-ADE
renal	I-ADE
impairment	I-ADE
)	O
are	O
described	O
.	O

-DOCSTART-	2923

Methimazole	B-Drug
-	O
associated	O
cholestatic	B-ADE
liver	I-ADE
injury	I-ADE
:	O
case	O
report	O
and	O
brief	O
literature	O
review	O
.	O

-DOCSTART-	1757

Usefulness	O
of	O
antiplatelet	O
drugs	O
in	O
the	O
management	O
of	O
heparin	B-Drug
-	O
associated	O
thrombocytopenia	B-ADE
and	O
thrombosis	B-ADE
.	O

-DOCSTART-	4019

We	O
report	O
an	O
unusually	O
short	O
lived	O
and	O
asymptomatic	O
episode	O
of	O
severe	O
cisplatin	B-Drug
-	O
induced	O
renal	B-ADE
tubular	I-ADE
salt	I-ADE
wasting	I-ADE
in	O
a	O
fit	O
41-year	O
-	O
old	O
patient	O
with	O
malignant	O
teratoma	O
.	O

-DOCSTART-	1371

We	O
report	O
an	O
unusual	O
case	O
of	O
massive	O
fluoxetine	B-Drug
ingestion	O
resulting	O
in	O
neurological	B-ADE
and	I-ADE
cardiovascular	I-ADE
toxicity	I-ADE
resulting	O
in	O
death	B-ADE
.	O

-DOCSTART-	439

A	O
62-year	O
-	O
old	O
woman	O
treated	O
with	O
pranlukast	B-Drug
for	O
2	O
months	O
developed	O
interstitial	B-ADE
pneumonitis	I-ADE
with	O
a	O
high	B-ADE
fever	I-ADE
.	O

-DOCSTART-	2656

Amiodarone	B-Drug
induced	O
torsades	B-ADE
de	I-ADE
pointe	I-ADE
.	O

-DOCSTART-	74

We	O
conclude	O
that	O
the	O
presence	O
of	O
this	O
metabolic	O
defect	O
combined	O
with	O
topical	O
5-FU	B-Drug
(	O
a	O
drug	O
demonstrating	O
a	O
narrow	O
therapeutic	O
index	O
)	O
results	O
in	O
the	O
unusual	O
presentation	O
of	O
life	B-ADE
-	I-ADE
threatening	I-ADE
toxicity	I-ADE
after	O
treatment	O
with	O
a	O
topical	O
drug	O
.	O

-DOCSTART-	1574

Acute	B-ADE
unilateral	I-ADE
total	I-ADE
visual	I-ADE
loss	I-ADE
after	O
retrogasserian	O
phenol	B-Drug
injection	O
for	O
the	O
treatment	O
of	O
trigeminal	O
neuralgia	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	209

When	O
cyanamide	B-Drug
-	O
treated	O
alcoholics	O
relapse	O
into	O
drinking	O
,	O
more	O
severe	O
inflammation	B-ADE
develops	O
in	O
the	O
liver	O
.	O

-DOCSTART-	2803

Unexpected	O
severe	O
reversible	O
cyclosporine	B-Drug
A	I-Drug
-	O
induced	O
nephrotoxicity	B-ADE
in	O
a	O
patient	O
with	O
systemic	O
lupus	O
erythematosus	O
and	O
tubulointerstitial	O
renal	O
disease	O
.	O

-DOCSTART-	1302

Corneal	B-ADE
endothelial	I-ADE
deposits	I-ADE
associated	O
with	O
rifabutin	B-Drug
use	O
.	O

-DOCSTART-	3588

Fulminant	B-ADE
hepatitis	I-ADE
with	O
severe	B-ADE
lactate	I-ADE
acidosis	I-ADE
in	O
HIV	O
-	O
infected	O
patients	O
on	O
didanosine	B-Drug
therapy	O
.	O

-DOCSTART-	3204

The	O
gynecomastia	B-ADE
regressed	O
when	O
the	O
theophylline	B-Drug
was	O
discontinued	O
.	O

-DOCSTART-	2745

We	O
wish	O
to	O
call	O
for	O
cautious	O
approach	O
at	O
time	O
of	O
cessation	O
of	O
prolonged	O
ACTH	B-Drug
therapy	O
because	O
of	O
possible	O
unexpected	O
and	O
only	O
partially	O
understood	O
hazardous	O
side	O
effects	O
such	O
as	O
hyperkalemia	B-ADE
.	O

-DOCSTART-	783

Treatment	O
of	O
lithium	B-Drug
-	O
induced	O
diabetes	B-ADE
insipidus	I-ADE
with	O
amiloride	O
.	O

-DOCSTART-	2021

Adult	B-ADE
respiratory	I-ADE
distress	I-ADE
syndrome	I-ADE
after	O
treatment	O
with	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
and	O
ribavirin	B-Drug
.	O

-DOCSTART-	2405

Of	O
371	O
patients	O
treated	O
with	O
8MOP	B-Drug
,	O
three	O
(	O
0.8	O
%	O
)	O
developed	O
an	O
acute	B-ADE
dermatitis	I-ADE
in	O
the	O
PUVA	O
-	O
treated	O
areas	O
.	O

-DOCSTART-	2722

A	O
57-year	O
-	O
old	O
woman	O
presented	O
with	O
a	O
3-week	O
history	O
of	O
dysphagia	B-ADE
for	I-ADE
solids	I-ADE
,	O
6	O
months	O
after	O
starting	O
treatment	O
with	O
nifedipine	B-Drug
.	O

-DOCSTART-	2819

We	O
describe	O
a	O
63	O
year	O
old	O
woman	O
with	O
a	O
suppurative	O
mediastinitis	O
,	O
treated	O
with	O
continuous	O
PI	B-Drug
irrigation	O
who	O
developed	O
an	O
acute	B-ADE
oliguric	I-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	4023

Phenolphthalein	B-Drug
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
.	O

-DOCSTART-	227

PATIENTS	O
:	O
Three	O
patients	O
developed	O
a	O
reproductive	B-ADE
endocrine	I-ADE
disorder	I-ADE
during	O
treatment	O
with	O
valproate	B-Drug
.	O

-DOCSTART-	3847

Terbinafine	B-Drug
-	O
induced	O
cholestatic	B-ADE
liver	I-ADE
disease	I-ADE
.	O

-DOCSTART-	1668

This	O
report	O
describes	O
a	O
13-year	O
-	O
old	O
female	O
with	O
a	O
right	O
frontal	O
high	O
-	O
grade	O
glioma	O
and	O
complex	O
partial	O
seizures	O
who	O
developed	O
localized	B-ADE
purpura	I-ADE
after	O
23	O
months	O
of	O
lamotrigine	B-Drug
monotherapy	O
.	O

-DOCSTART-	3750

A	O
macrophage	B-ADE
activation	I-ADE
syndrome	I-ADE
,	O
possibly	O
related	O
to	O
methotrexate	B-Drug
toxicity	I-ADE
,	O
developed	O
in	O
a	O
boy	O
with	O
systemic	O
juvenile	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	1073

Although	O
neurotoxicity	B-ADE
is	O
a	O
frequent	O
complication	O
of	O
methotrexate	B-Drug
therapy	O
,	O
fatal	B-ADE
acute	I-ADE
neurotoxicity	I-ADE
is	O
extremely	O
uncommon	O
,	O
especially	O
in	O
adults	O
.	O

-DOCSTART-	1764

We	O
report	O
a	O
case	O
of	O
Thrombotic	B-ADE
Thrombocytopenic	I-ADE
Purpura	I-ADE
occurring	O
as	O
an	O
allergic	O
response	O
to	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
therapy	O
(	O
Bactrim	O
,	O
Septra	O
)	O
in	O
a	O
Jehovah	O
's	O
Witness	O
patient	O
.	O

-DOCSTART-	2327

Sertraline	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
in	O
an	O
elderly	O
patient	O
with	O
dementia	O
and	O
comorbidities	O
.	O

-DOCSTART-	663

BACKGROUND	O
:	O
Gemcitabine	B-Drug
has	O
mild	O
renal	B-ADE
toxicity	I-ADE
,	O
but	O
cases	O
of	O
gemcitabine	B-Drug
-	O
associated	O
hemolytic	B-ADE
-	I-ADE
uremic	I-ADE
syndrome	I-ADE
(	O
HUS	B-ADE
)	O
have	O
been	O
reported	O
.	O

-DOCSTART-	2153

Acute	B-ADE
coronary	I-ADE
syndromes	I-ADE
can	O
be	O
associated	O
with	O
the	O
infusion	O
of	O
rituximab	B-Drug
.	O

-DOCSTART-	2108

Cephalosporin	B-Drug
-	O
induced	O
leukopenia	B-ADE
following	O
rechallenge	O
with	O
cefoxitin	O
.	O

-DOCSTART-	66

PURPOSE	O
:	O
To	O
report	O
two	O
cases	O
in	O
which	O
topical	O
brimonidine	B-Drug
resulted	O
in	O
apparent	O
central	B-ADE
nervous	I-ADE
system	I-ADE
depression	I-ADE
and	O
unresponsiveness	O
in	O
an	O
infant	O
.	O

-DOCSTART-	1337

Clinical	O
course	O
of	O
macular	B-ADE
edema	I-ADE
in	O
two	O
cases	O
of	O
interferon	B-Drug
-	O
associated	O
retinopathy	B-ADE
observed	O
by	O
optical	O
coherence	O
tomography	O
.	O

-DOCSTART-	3573

Celiprolol	B-Drug
pneumonitis	B-ADE
.	O

-DOCSTART-	3013

Methotrexate	B-Drug
-	O
induced	O
diffuse	B-ADE
interstitial	I-ADE
pulmonary	I-ADE
fibrosis	I-ADE
.	O

-DOCSTART-	661

Rofecoxib	B-Drug
,	O
used	O
for	O
dysmenorrhea	O
,	O
caused	O
a	O
herpetiform	B-ADE
fixed	I-ADE
drug	I-ADE
eruption	I-ADE
predominantly	O
involving	O
the	O
lips	O
with	O
classic	O
clinical	O
and	O
histological	O
findings	O
in	O
a	O
red	B-ADE
-	I-ADE
brown	I-ADE
lesion	I-ADE
on	O
the	O
dorsal	O
hand	O
.	O

-DOCSTART-	3340

The	O
fluorine	O
contained	O
in	O
niflumic	B-Drug
acid	I-Drug
induced	O
a	O
marked	O
densification	B-ADE
of	I-ADE
trabecular	I-ADE
bone	I-ADE
in	O
all	O
3	O
cases	O
.	O

-DOCSTART-	3537

We	O
discuss	O
our	O
observations	O
in	O
the	O
cases	O
of	O
two	O
patients	O
with	O
acyclovir	B-Drug
neurotoxicity	B-ADE
and	O
review	O
the	O
findings	O
of	O
all	O
previous	O
reports	O
in	O
the	O
English	O
language	O
literature	O
.	O

-DOCSTART-	2591

The	O
fever	B-ADE
abated	O
promptly	O
following	O
discontinuation	O
of	O
acyclovir	B-Drug
,	O
and	O
radiographic	O
abnormalities	O
resolved	O
over	O
ten	O
days	O
.	O

-DOCSTART-	533

Serotonin	B-ADE
syndrome	I-ADE
caused	O
by	O
selective	O
serotonin	O
reuptake	O
-	O
inhibitors	O
-	O
metoclopramide	B-Drug
interaction	O
.	O

-DOCSTART-	1099

A	O
patient	O
with	O
monocular	O
open	O
-	O
angle	O
glaucoma	O
had	O
trichiasis	B-ADE
,	O
a	O
condition	O
associated	O
with	O
the	O
use	O
of	O
a	O
prostaglandin	B-Drug
analog	O
.	O

-DOCSTART-	1908

Sirolimus	B-ADE
-	I-ADE
eluting	I-ADE
stent	I-ADE
thrombosis	I-ADE
several	O
years	O
after	O
clopidogrel	B-Drug
discontinuation	O
.	O

-DOCSTART-	2324

CONCLUSIONS	O
:	O
This	O
patient	O
's	O
rhabdomyolysis	B-ADE
was	O
probably	O
induced	O
by	O
sertraline	B-Drug
therapy	O
.	O

-DOCSTART-	2029

Type	B-ADE
1	I-ADE
diabetes	I-ADE
mellitus	I-ADE
provoked	O
by	O
peginterferon	B-Drug
alpha-2b	I-Drug
plus	O
ribavirin	B-Drug
treatment	O
for	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	3950

Although	O
dyspnea	B-ADE
associated	O
with	O
verapamil	B-Drug
administration	O
has	O
been	O
reported	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
elderly	O
asymptomatic	O
asthmatic	O
patient	O
with	O
hypertension	O
who	O
developed	O
an	O
acute	B-ADE
asthma	I-ADE
attack	O
following	O
sustained	O
-	O
release	O
verapamil	B-Drug
administration	O
.	O

-DOCSTART-	542

Warfarin	B-Drug
-	O
associated	O
bleeding	B-ADE
complication	O
saved	O
life	O
.	O

-DOCSTART-	2443

We	O
report	O
a	O
case	O
of	O
Zidovudine	B-Drug
induced	O
anaemia	B-ADE
and	O
bone	B-ADE
marrow	I-ADE
aplasia	I-ADE
in	O
a	O
patient	O
infected	O
with	O
HIV	O
.	O

-DOCSTART-	69

Anterior	B-ADE
lumbosacral	I-ADE
radiculopathy	I-ADE
after	O
intrathecal	O
methotrexate	B-Drug
treatment	O
.	O

-DOCSTART-	765

Interferon	B-Drug
-	I-Drug
alpha	I-Drug
(	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
)	O
may	O
precipitate	O
or	O
exacerbate	O
the	O
occurrence	O
of	O
MPGN	B-ADE
.	O

-DOCSTART-	3552

During	O
and	O
after	O
IFN	B-Drug
therapy	O
we	O
should	O
consider	O
the	O
possibility	O
of	O
occurrence	O
of	O
IDDM	B-ADE
as	O
well	O
as	O
other	O
autoimmune	O
diseases	O
and	O
observe	O
the	O
clinical	O
course	O
carefully	O
.	O

-DOCSTART-	1376

Transient	B-ADE
global	I-ADE
amnesia	I-ADE
after	O
clioquinol	B-Drug
:	O
five	O
personal	O
observations	O
from	O
outside	O
Japan	O
.	O

-DOCSTART-	780

The	O
sulfonamides	B-Drug
are	O
the	O
best	O
verified	O
drug	O
-	O
trigger	O
for	O
erythema	B-ADE
multiforme	I-ADE
and	O
Stevens	B-ADE
-	I-ADE
Johnson	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	748

This	O
case	O
highlights	O
the	O
need	O
to	O
monitor	O
liver	O
enzymes	O
in	O
patients	O
treated	O
with	O
6-TG	O
and	O
identifies	O
the	O
need	O
for	O
additional	O
research	O
focused	O
on	O
the	O
mechanism	O
of	O
thiopurine	B-Drug
-	O
induced	O
hepatic	B-ADE
injury	I-ADE
.	O

-DOCSTART-	64

Apparent	O
central	B-ADE
nervous	I-ADE
system	I-ADE
depression	I-ADE
in	O
infants	O
after	O
the	O
use	O
of	O
topical	O
brimonidine	B-Drug
.	O

-DOCSTART-	3977

An	O
elderly	O
man	O
with	O
procainamide	B-Drug
hydrochloride	I-Drug
-	O
induced	O
lupus	B-ADE
syndrome	I-ADE
had	O
a	O
circulating	O
anticoagulant	O
against	O
factor	O
XI	O
and	O
a	O
biologic	O
false	O
-	O
positive	O
(	O
BFP	O
)	O
test	O
result	O
for	O
syphilis	O
.	O

-DOCSTART-	4008

We	O
describe	O
a	O
patient	O
with	O
metastatic	O
prostate	O
cancer	O
who	O
developed	O
nonoliguric	B-ADE
renal	I-ADE
failure	I-ADE
during	O
treatment	O
with	O
suramin	B-Drug
.	O

-DOCSTART-	825

Although	O
it	O
would	O
be	O
expected	O
that	O
,	O
like	O
other	O
type	O
IA	O
toxicities	O
,	O
diphenhydramine	B-Drug
-	O
induced	O
cardiotoxicity	B-ADE
could	O
be	O
responsive	O
to	O
hypertonic	O
sodium	O
bicarbonate	O
,	O
this	O
finding	O
is	O
largely	O
unappreciated	O
.	O

-DOCSTART-	865

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
significant	O
hepatic	B-ADE
and	I-ADE
renal	I-ADE
failure	I-ADE
with	O
the	O
use	O
of	O
argatroban	B-Drug
in	O
a	O
patient	O
with	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
(	O
HIT	O
)	O
requiring	O
continuous	O
veno	O
-	O
veno	O
hemodialysis	O
(	O
CVVHD	O
)	O
.	O

-DOCSTART-	3540

Amebic	B-ADE
abscess	I-ADE
of	I-ADE
the	I-ADE
spleen	I-ADE
complicated	O
by	O
metronidazole	B-Drug
-	O
induced	O
neurotoxicity	B-ADE
:	O
case	O
report	O
.	O

-DOCSTART-	1375

The	O
clinical	O
aspect	O
closely	O
resembled	O
classical	O
transient	B-ADE
global	I-ADE
amnesia	I-ADE
but	O
the	O
episode	O
after	O
clioquinol	B-Drug
lasted	O
longer	O
(	O
24	O
hours	O
to	O
three	O
days	O
)	O
and	O
a	O
more	O
or	O
less	O
extensive	O
retrograde	B-ADE
amnesia	I-ADE
persisted	O
permanently	O
.	O

-DOCSTART-	612

Valproate	B-Drug
-	O
induced	O
hyperammonemia	B-ADE
as	O
a	O
cause	O
of	O
altered	B-ADE
mental	I-ADE
status	I-ADE
.	O

-DOCSTART-	370

RESULTS	O
:	O
The	O
patient	O
,	O
a	O
27-year	O
-	O
old	O
married	O
Japanese	O
woman	O
with	O
borderline	O
personality	O
disorder	O
,	O
developed	O
an	O
increased	B-ADE
libido	I-ADE
with	O
the	O
administration	O
of	O
fluvoxamine	B-Drug
.	O

-DOCSTART-	3838

Loperamide	B-ADE
poisoning	I-ADE
in	O
the	O
dog	O
.	O

-DOCSTART-	283

The	O
field	B-ADE
defects	I-ADE
and	O
some	O
electrophysiological	O
abnormalities	O
persist	O
when	O
vigabatrin	B-Drug
therapy	O
is	O
withdrawn	O
.	O

-DOCSTART-	3505

Case	O
report	O
:	O
mannitol	B-Drug
nephrotoxicity	B-ADE
syndrome	I-ADE
:	O
role	O
of	O
hemodialysis	O
and	O
postulate	O
of	O
mechanisms	O
.	O

-DOCSTART-	144

Ten	O
to	O
15	O
%	O
of	O
patients	O
treated	O
with	O
ifosfamide	B-Drug
develop	O
an	O
encephalopathy	B-ADE
.	O

-DOCSTART-	1396

Primary	O
CNS	B-ADE
lymphoma	I-ADE
regressed	O
on	O
withdrawal	O
of	O
MM	B-Drug
.	O

-DOCSTART-	1739

CONCLUSIONS	O
:	O
We	O
report	O
a	O
typical	O
symptoms	O
of	O
Charles	B-ADE
-	I-ADE
Bonnet	I-ADE
syndrome	I-ADE
(	O
CBS	B-ADE
)	O
in	O
patients	O
with	O
severe	O
AMD	O
after	O
intravitreal	O
Avastin	B-Drug
-	O
injections	O
.	O

-DOCSTART-	1154

We	O
report	O
two	O
young	O
patients	O
with	O
cystic	O
fibrosis	O
who	O
presented	O
with	O
acute	B-ADE
renal	I-ADE
insufficiency	I-ADE
after	O
2	O
-	O
3	O
weeks	O
of	O
oral	O
ciprofloxacin	B-Drug
therapy	O
.	O

-DOCSTART-	778

A	O
71-year	O
-	O
old	O
man	O
,	O
who	O
had	O
a	O
history	O
of	O
a	O
previous	O
bullous	B-ADE
drug	I-ADE
reaction	I-ADE
to	O
a	O
sulfonamide	B-Drug
,	O
began	O
receiving	O
an	O
ophthalmic	O
preparation	O
that	O
contained	O
sulfacetamide	O
sodium	O
.	O

-DOCSTART-	2130

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
report	O
the	O
concomitant	O
occurrence	O
of	O
multiple	B-ADE
squamous	I-ADE
cell	I-ADE
carcinomas	I-ADE
and	O
diffuse	B-ADE
nail	I-ADE
hyperpigmentation	I-ADE
associated	O
with	O
hydroxyurea	B-Drug
treatment	O
,	O
and	O
to	O
describe	O
a	O
successful	O
therapeutic	O
approach	O
using	O
imiquimod	O
5	O
%	O
.	O

-DOCSTART-	1446

A	O
56-year	O
-	O
old	O
white	O
woman	O
with	O
a	O
diagnosis	O
of	O
reactive	O
depression	O
developed	O
severe	O
UI	B-ADE
after	O
a	O
30	O
days	O
'	O
treatment	O
with	O
venlafaxine	B-Drug
75	O
mg	O
/	O
day	O
.	O

-DOCSTART-	4141

The	O
vomiting	B-ADE
occurred	O
on	O
switching	O
to	O
different	O
pancreatic	O
enzymes	O
preparations	O
,	O
ie	O
,	O
Creon	B-Drug
10	I-Drug
,	O
Viokase	B-Drug
,	O
and	O
Pancrease	B-Drug
MT	I-Drug
16	I-Drug
.	O

-DOCSTART-	2223

We	O
report	O
the	O
case	O
of	O
a	O
51-year	O
-	O
old	O
man	O
in	O
whom	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
treatment	O
was	O
followed	O
by	O
recurrence	O
of	O
Graves	B-ADE
'	I-ADE
disease	I-ADE
10	O
years	O
after	O
thyroidectomy	O
was	O
performed	O
and	O
the	O
patient	O
was	O
declared	O
cured	O
.	O

-DOCSTART-	2340

CONCLUSION	O
:	O
A	O
26-year	O
-	O
old	O
man	O
with	O
bipolar	O
disorder	O
developed	O
hyperammonemia	B-ADE
three	O
weeks	O
after	O
initiating	O
carbamazepine	B-Drug
therapy	O
.	O

-DOCSTART-	2225

The	O
authors	O
describe	O
a	O
case	O
of	O
interstitial	B-ADE
granulomatous	I-ADE
dermatitis	I-ADE
associated	O
with	O
darifenacin	B-Drug
.	O

-DOCSTART-	813

A	O
lupus	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
associated	O
with	O
infliximab	B-Drug
therapy	O
.	O

-DOCSTART-	1166

During	O
analysis	O
of	O
28	O
patients	O
receiving	O
CAP	B-Drug
with	O
concomitant	O
radiation	O
(	O
XRT	O
)	O
for	O
pancreatic	O
cancer	O
(	O
resected	O
or	O
locally	O
advanced	O
)	O
,	O
two	O
patients	O
developed	O
signs	O
and	O
symptoms	O
consistent	O
with	O
peripheral	B-ADE
neuropathy	I-ADE
.	O

-DOCSTART-	3318

Liver	B-ADE
disease	I-ADE
induced	O
by	O
perhexiline	B-Drug
maleate	I-Drug
.	O

-DOCSTART-	2687

Both	O
patients	O
developed	O
hypoadrenalism	B-ADE
while	O
on	O
o	B-Drug
,	I-Drug
p'-DDD	I-Drug
and	O
apparently	O
adequate	O
dexamethasone	O
replacement	O
therapy	O
.	O

-DOCSTART-	4207

Dental	B-ADE
and	I-ADE
gingival	I-ADE
pain	I-ADE
as	O
side	O
effects	O
of	O
niacin	B-Drug
therapy	O
.	O

-DOCSTART-	795

Intrathecal	O
methotrexate	B-Drug
-	O
induced	O
acute	B-ADE
cerebellar	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	2036

Disseminated	B-ADE
eruptive	I-ADE
giant	I-ADE
mollusca	I-ADE
contagiosa	I-ADE
in	O
an	O
adult	O
psoriasis	O
patient	O
during	O
efalizumab	B-Drug
therapy	O
.	O

-DOCSTART-	355

As	O
these	O
cases	O
revealed	O
,	O
close	O
monitoring	O
of	O
blood	O
chemistry	O
is	O
mandatory	O
after	O
starting	O
spironolactone	O
,	O
and	O
patients	O
should	O
be	O
advised	O
to	O
stop	O
spironolactone	B-Drug
immediately	O
if	O
diarrhoea	B-ADE
develops	O
.	O

-DOCSTART-	1221

The	O
ulcer	B-ADE
did	O
not	O
respond	O
to	O
antibiotic	O
treatment	O
and	O
healed	O
shortly	O
after	O
withholding	O
ATRA	B-Drug
.	O

-DOCSTART-	4227

CONCLUSION	O
:	O
We	O
report	O
a	O
case	O
of	O
the	O
use	O
of	O
pamidronate	O
for	O
significant	O
hypercalcemia	B-ADE
secondary	O
to	O
acute	B-ADE
vitamin	I-ADE
D	I-ADE
poisoning	I-ADE
.	O

-DOCSTART-	1297

We	O
propose	O
a	O
mechanism	O
of	O
vancomycin	B-Drug
-	O
induced	O
mast	O
cell	O
degranulation	O
and	O
subsequent	O
release	O
of	O
eosinophil	O
chemotactic	O
factor	O
as	O
a	O
cause	O
of	O
CSFE	B-ADE
.	O

-DOCSTART-	2053

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
present	O
the	O
first	O
case	O
-	O
series	O
of	O
posterior	B-ADE
reversible	I-ADE
encephalopathy	I-ADE
syndrome	I-ADE
(	O
PRES	B-ADE
)	O
associated	O
with	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
treatment	O
.	O

-DOCSTART-	2571

This	O
article	O
describes	O
a	O
patient	O
with	O
suspected	O
ciprofloxacin	B-Drug
-	O
induced	O
interstitial	B-ADE
nephritis	I-ADE
.	O

-DOCSTART-	2597

Hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
in	O
a	O
patient	O
on	O
cis	B-Drug
-	I-Drug
platinum	I-Drug
,	O
vinblastine	B-Drug
and	O
bleomycin	B-Drug
.	O

-DOCSTART-	2200

Acute	B-ADE
ischaemia	I-ADE
of	I-ADE
the	I-ADE
leg	I-ADE
following	O
accidental	O
intra	O
-	O
arterial	O
injection	O
of	O
dissolved	O
flunitrazepam	B-Drug
tablets	O
.	O

-DOCSTART-	856

Only	O
one	O
case	O
of	O
a	O
generalized	B-ADE
maculopapular	I-ADE
rash	I-ADE
with	O
enoxaparin	B-Drug
has	O
been	O
reported	O
in	O
Europe	O
.	O

-DOCSTART-	965

Infectious	B-ADE
toxicity	I-ADE
of	O
dexamethasone	B-Drug
during	O
all	O
remission	O
-	O
induction	O
chemotherapy	O
:	O
report	O
of	O
two	O
cases	O
and	O
literature	O
review	O
.	O

-DOCSTART-	4101

STUDY	O
DESIGN	O
:	O
Case	O
reports	O
are	O
presented	O
of	O
three	O
premature	O
infants	O
(	O
mean	O
gestational	O
age	O
27	O
weeks	O
)	O
cared	O
for	O
in	O
the	O
intensive	O
care	O
nursery	O
in	O
whom	O
clinically	O
significant	O
septal	B-ADE
hypertrophy	I-ADE
and	O
left	B-ADE
ventricular	I-ADE
outflow	I-ADE
tract	I-ADE
obstruction	I-ADE
developed	O
during	O
dexamethasone	B-Drug
treatment	O
for	O
bronchopulmonary	O
dysplasia	O
.	O

-DOCSTART-	3807

Potential	O
mechanisms	O
regarding	O
the	O
pathophysiology	O
of	O
lithium	B-Drug
-	O
associated	O
CDI	B-ADE
are	O
discussed	O
.	O

-DOCSTART-	1662

We	O
believe	O
this	O
is	O
the	O
first	O
report	O
of	O
intrathecal	O
diamorphine	B-Drug
causing	O
anaphylaxis	B-ADE
.	O

-DOCSTART-	3826

Acute	B-ADE
pulmonary	I-ADE
reactions	I-ADE
to	O
nitrofurantoin	B-Drug
are	O
an	O
uncommon	O
side	O
effect	O
of	O
therapy	O
and	O
can	O
cause	O
minor	O
or	O
life	O
-	O
threatening	O
pulmonary	B-ADE
dysfunction	I-ADE
.	O

-DOCSTART-	198

Perinatal	O
vasoconstrictive	O
renal	B-ADE
insufficiency	I-ADE
associated	O
with	O
maternal	O
nimesulide	B-Drug
use	O
.	O

-DOCSTART-	472

CONCLUSIONS	O
:	O
Cicatrization	O
in	O
the	O
substantia	O
propria	O
of	O
the	O
conjunctiva	O
by	O
excessive	O
lymphocytic	O
infiltration	O
after	O
topically	O
administered	O
antiglaucoma	O
drugs	O
including	O
dipivefrin	B-Drug
is	O
a	O
possible	O
mechanism	O
of	O
action	O
for	O
entropion	B-ADE
.	O

-DOCSTART-	1641

Except	O
hypothyroidism	B-ADE
after	O
radioiodine	B-Drug
treatment	O
(	O
euthyroid	O
under	O
substitutional	O
therapy	O
)	O
,	O
she	O
suffered	O
from	O
no	O
other	O
diseases	O
.	O

-DOCSTART-	263

The	O
intramuscular	O
challenge	O
test	O
with	O
25	O
UI	O
of	O
Miacalcic	B-Drug
was	O
positive	O
with	O
an	O
immediate	O
anaphylactic	B-ADE
reaction	I-ADE
.	O

-DOCSTART-	4112

A	O
syndrome	B-ADE
of	I-ADE
increased	I-ADE
affect	I-ADE
in	O
response	O
to	O
risperidone	B-Drug
among	O
patients	O
with	O
schizophrenia	O
.	O

-DOCSTART-	2821

D	B-Drug
-	I-Drug
penicillamine	I-Drug
induced	O
crescentic	B-ADE
glomerulonephritis	I-ADE
:	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	4003

Heat	B-ADE
stroke	I-ADE
-	I-ADE
like	I-ADE
episode	I-ADE
in	O
a	O
child	O
caused	O
by	O
zonisamide	B-Drug
.	O

-DOCSTART-	2884

Phenytoin	B-Drug
-	O
induced	O
hypersensitivity	B-ADE
reactions	I-ADE
.	O

-DOCSTART-	3262

Disopyramide	B-Drug
(	O
Norpace	B-Drug
)	O
-	O
induced	O
hypoglycemia	B-ADE
.	O

-DOCSTART-	1612

Cutaneous	B-ADE
eruptions	I-ADE
occur	O
in	O
3	O
%	O
of	O
individuals	O
administered	O
carbamazepine	B-Drug
.	O

-DOCSTART-	1055

Ten	O
years	O
of	O
behavioral	O
data	O
are	O
presented	O
to	O
support	O
the	O
hypothesis	O
that	O
phenobarbital	B-Drug
was	O
exacerbating	O
maladaptive	B-ADE
behaviors	I-ADE
.	O

-DOCSTART-	4185

Severe	B-ADE
akathisia	I-ADE
during	O
olanzapine	B-Drug
treatment	O
of	O
acute	O
schizophrenia	O
.	O

-DOCSTART-	1448

Venlafaxine	B-Drug
-	O
induced	O
urinary	B-ADE
incontinence	I-ADE
resolved	O
after	O
switching	O
to	O
sertraline	O
.	O

-DOCSTART-	1777

Fatal	B-ADE
venous	I-ADE
thrombembolism	I-ADE
complicating	O
imatinib	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
metastatic	O
gastrointestinal	O
stromal	O
tumor	O
.	O

-DOCSTART-	491

Systemic	B-ADE
allergic	I-ADE
contact	I-ADE
dermatitis	I-ADE
to	O
8-methoxypsoralen	B-Drug
(	O
8-MOP	B-Drug
)	O
.	O

-DOCSTART-	573

Minimal	B-ADE
change	I-ADE
nephrotic	I-ADE
syndrome	I-ADE
developing	O
during	O
postoperative	O
interferon	B-Drug
-	I-Drug
beta	I-Drug
therapy	O
for	O
malignant	O
melanoma	O
.	O

-DOCSTART-	3404

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
a	O
high	O
dose	O
combined	O
with	O
a	O
short	O
infusion	O
time	O
increases	O
the	O
risk	O
of	O
anaphylactoid	B-ADE
reactions	I-ADE
with	O
the	O
administration	O
of	O
intraperitoneal	O
cisplatin	B-Drug
.	O

-DOCSTART-	3982

Overdose	O
of	O
magnesium	B-Drug
sulfate	I-Drug
in	O
combination	O
with	O
renal	O
insufficiency	O
,	O
hypocalcemia	O
,	O
or	O
compromise	O
of	O
intestinal	O
integrity	O
may	O
predispose	O
horses	O
to	O
magnesium	B-ADE
toxicosis	I-ADE
.	O

-DOCSTART-	2253

A	O
previous	O
study	O
of	O
patients	O
with	O
"	O
quinine	B-Drug
-	O
associated	O
TTP	B-ADE
/	I-ADE
HUS	I-ADE
"	O
found	O
that	O
ADAMTS13	O
activities	O
were	O
not	O
abnormal	O
in	O
12/12	O
patients	O
.	O

-DOCSTART-	1284

A	O
74-year	O
-	O
old	O
hypercholestrerolaemic	O
woman	O
taking	O
cerivastatin	B-Drug
(	O
0.15	O
mg	O
/	O
day	O
)	O
for	O
22	O
days	O
complained	O
of	O
general	O
muscle	B-ADE
weakness	I-ADE
and	O
muscle	B-ADE
pain	I-ADE
.	O

-DOCSTART-	2183

Drug	O
-	O
induced	O
fever	B-ADE
should	O
be	O
considered	O
in	O
patients	O
who	O
have	O
unexplained	O
high	O
temperatures	O
during	O
diltiazem	B-Drug
therapy	O
.	O

-DOCSTART-	3347

The	O
introduction	O
of	O
para	B-Drug
-	I-Drug
aminosalicylic	I-Drug
acid	I-Drug
(	O
PAS	B-Drug
)	O
led	O
to	O
hypoglycaemic	B-ADE
coma	I-ADE
.	O

-DOCSTART-	3462

We	O
stress	O
the	O
potential	O
of	O
benzarone	B-Drug
to	O
cause	O
hepatotoxicity	B-ADE
,	O
which	O
usually	O
resembles	O
severe	B-ADE
chronic	I-ADE
active	I-ADE
hepatitis	I-ADE
.	O

-DOCSTART-	422

CONCLUSIONS	O
:	O
We	O
report	O
the	O
first	O
case	O
of	O
gemcitabine	B-Drug
-	O
induced	O
LABD	B-ADE
.	O

-DOCSTART-	3898

After	O
induction	O
of	O
general	O
anesthesia	O
and	O
administration	O
of	O
a	O
standard	O
dose	O
of	O
intravenous	O
esmolol	B-Drug
hydrochloride	I-Drug
,	O
her	O
cardiac	O
rhythm	O
progressed	O
to	O
asystole	B-ADE
.	O

-DOCSTART-	1577

Drug	O
induced	O
liver	B-ADE
injury	I-ADE
secondary	O
to	O
interferon	B-Drug
-	I-Drug
beta	I-Drug
(	O
IFN	B-Drug
-	I-Drug
beta	I-Drug
)	O
in	O
multiple	O
sclerosis	O
.	O

-DOCSTART-	2512

Subglottic	B-ADE
stenosis	I-ADE
in	O
Wegener	O
's	O
granulomatosis	O
:	O
development	O
during	O
cyclophosphamide	B-Drug
treatment	O
with	O
response	O
to	O
carbon	O
dioxide	O
laser	O
therapy	O
.	O

-DOCSTART-	2897

After	O
therapy	O
with	O
parenteral	O
amiodarone	B-Drug
(	O
2300	O
mg	O
in	O
3	O
days	O
)	O
and	O
other	O
measures	O
,	O
signs	O
of	O
congestive	O
heart	O
failure	O
disappeared	O
;	O
subsequently	O
the	O
patient	O
developed	O
jaundice	B-ADE
,	O
marked	B-ADE
increase	I-ADE
in	I-ADE
serum	I-ADE
transaminase	I-ADE
levels	I-ADE
and	O
fall	B-ADE
in	I-ADE
prothrombin	I-ADE
time	I-ADE
,	O
and	O
histologic	O
changes	O
of	O
severe	B-ADE
centrilobular	I-ADE
necrosis	I-ADE
were	O
observed	O
in	O
hepatic	O
biopsy	O
.	O

-DOCSTART-	1696

Acute	B-ADE
eosinophilic	I-ADE
pneumonia	I-ADE
caused	O
by	O
calcium	B-Drug
stearate	I-Drug
,	O
an	O
additive	O
agent	O
for	O
an	O
oral	O
antihistaminic	O
medication	O
.	O

-DOCSTART-	2506

A	O
case	O
of	O
the	O
Rett	O
syndrome	O
with	O
acute	B-ADE
encephalopathy	I-ADE
induced	O
during	O
calcium	B-Drug
hopantenate	I-Drug
treatment	O
.	O

-DOCSTART-	175

Flecainide	B-Drug
is	O
a	O
rare	O
cause	O
of	O
hypersensitivity	B-ADE
pneumonitis	I-ADE
,	O
and	O
few	O
cases	O
have	O
been	O
reported	O
.	O

-DOCSTART-	1979

This	O
case	O
demonstrates	O
the	O
value	O
of	O
DWI	O
in	O
evaluation	O
and	O
diagnosis	O
of	O
sub	B-ADE
-	I-ADE
acute	I-ADE
toxic	I-ADE
leukoencephalopathy	I-ADE
in	O
patients	O
being	O
treated	O
with	O
methotrexate	B-Drug
.	O

-DOCSTART-	1363

Since	O
1979	O
,	O
over	O
30	O
published	O
case	O
reports	O
have	O
documented	O
the	O
relationship	O
between	O
phenylpropanolamine	B-Drug
and	O
stroke	B-ADE
.	O

-DOCSTART-	2807

Evidence	O
obtained	O
indicated	O
that	O
the	O
Reye	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
might	O
be	O
caused	O
by	O
calcium	B-Drug
hopantenate	I-Drug
possibly	O
due	O
to	O
the	O
induction	O
of	O
pantothenic	B-ADE
acid	I-ADE
deficiency	I-ADE
.	O

-DOCSTART-	395

Ticlopidine	B-Drug
-	O
induced	O
interstitial	B-ADE
pulmonary	I-ADE
disease	I-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	4081

Stroke	B-ADE
is	O
an	O
infrequent	O
but	O
recognized	O
complication	O
of	O
heroin	B-Drug
addiction	O
.	O

-DOCSTART-	3941

Four	O
cases	O
of	O
adverse	B-ADE
experiences	I-ADE
with	O
clonidine	B-Drug
are	O
described	O
.	O

-DOCSTART-	2154

Acute	B-ADE
coronary	I-ADE
syndromes	I-ADE
complicating	O
the	O
first	O
infusion	O
of	O
rituximab	B-Drug
.	O

-DOCSTART-	208

Cyanamide	B-Drug
-	O
induced	O
liver	B-ADE
dysfunction	I-ADE
after	O
abstinence	O
in	O
alcoholics	O
:	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
study	O
on	O
four	O
cases	O
.	O

-DOCSTART-	4269

Eosinophilia	B-ADE
caused	O
by	O
clozapine	B-Drug
was	O
observed	O
in	O
challenge	O
,	O
preceded	O
by	O
a	O
faster	O
neutrophil	O
production	O
and	O
consecutive	O
decrease	O
(	O
z	O
=	O
2.27	O
,	O
p	O
=	O
0.01	O
)	O
.	O

-DOCSTART-	826

Diphenhydramine	B-Drug
-	O
induced	O
wide	O
complex	O
dysrhythmia	B-ADE
responds	O
to	O
treatment	O
with	O
sodium	O
bicarbonate	O
.	O

-DOCSTART-	899

Sulfasalazine	B-Drug
-	O
induced	O
lung	B-ADE
disorder	I-ADE
is	O
an	O
extremely	O
rare	O
entity	O
which	O
must	O
be	O
considered	O
in	O
all	O
ulcerative	B-ADE
colitis	I-ADE
patients	O
while	O
on	O
sulfasalazine	B-Drug
therapy	O
,	O
despite	O
the	O
absence	O
of	O
pulmonary	O
symptomatology	O
.	O

-DOCSTART-	2944

Ampicillin	B-Drug
increased	O
the	O
preexisting	O
electrical	B-ADE
decrement	I-ADE
in	O
three	O
rabbits	O
with	O
experimental	O
autoimmune	O
myasthenia	O
gravis	O
while	O
the	O
drug	O
had	O
no	O
deleterious	O
effects	O
in	O
less	O
affected	O
or	O
normal	O
animals	O
.	O

-DOCSTART-	2920

Generalized	B-ADE
pustular	I-ADE
psoriasis	I-ADE
precipitated	O
by	O
trazodone	B-Drug
in	O
the	O
treatment	O
of	O
depression	O
.	O

-DOCSTART-	1888

We	O
describe	O
in	O
detail	O
the	O
first	O
U.S.	O
case	O
report	O
,	O
of	O
a	O
4(1/2	O
)	O
-	O
year	O
-	O
old	O
boy	O
who	O
experienced	O
angioedema	B-ADE
during	O
treatment	O
with	O
oxcarbazepine	B-Drug
.	O

-DOCSTART-	961

In	O
our	O
patient	O
,	O
an	O
objective	O
causality	O
scale	O
showed	O
that	O
therapeutic	O
doses	O
of	O
colchicine	B-Drug
for	O
FMF	O
were	O
the	O
definite	O
cause	O
of	O
myopathy	B-ADE
,	O
even	O
though	O
his	O
renal	O
and	O
hepatic	O
function	O
were	O
normal	O
.	O

-DOCSTART-	212

A	O
generalized	B-ADE
tonic	I-ADE
-	I-ADE
clonic	I-ADE
seizure	I-ADE
occurred	O
a	O
few	O
minutes	O
after	O
injection	O
of	O
the	O
morphine	O
antagonist	O
naloxone	B-Drug
.	O

-DOCSTART-	414

Although	O
no	O
coagulation	O
study	O
was	O
done	O
and	O
the	O
Meckel	O
's	O
diverticulum	O
is	O
normally	O
associated	O
with	O
bleeding	O
,	O
the	O
particular	O
intensity	O
of	O
the	O
following	O
hemorrhage	B-ADE
may	O
have	O
been	O
favored	O
by	O
metformin	B-Drug
.	O

-DOCSTART-	266

Minocycline	B-Drug
-	O
induced	O
autoimmune	B-ADE
hepatitis	I-ADE
is	O
usually	O
identical	O
to	O
sporadic	O
autoimmune	O
hepatitis	O
.	O

-DOCSTART-	2989

Fenclofenac	B-Drug
-	O
induced	O
selective	O
IgA	B-ADE
deficiency	I-ADE
in	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2881

Massive	B-ADE
pulmonary	I-ADE
embolism	I-ADE
complicating	O
streptokinase	B-Drug
treatment	O
for	O
deep	O
vein	O
thrombosis	O
.	O

-DOCSTART-	515

An	O
adult	O
male	O
presented	O
with	O
central	B-ADE
blindness	I-ADE
after	O
ingesting	O
methanol	B-Drug
.	O

-DOCSTART-	1722

Valvular	B-ADE
heart	I-ADE
disease	I-ADE
in	O
a	O
patient	O
taking	O
benfluorex	B-Drug
.	O

-DOCSTART-	4143

We	O
report	O
for	O
the	O
first	O
time	O
the	O
development	O
of	O
symptomatic	B-ADE
methemoglobinemia	I-ADE
after	O
an	O
acute	O
ingestion	O
of	O
divalproex	B-Drug
sodium	I-Drug
(	O
Depakote	B-Drug
)	O
,	O
resulting	O
in	O
serum	O
concentrations	O
10	O
times	O
greater	O
than	O
the	O
therapeutic	O
range	O
.	O

-DOCSTART-	3291

Marked	B-ADE
hyperkalemia	I-ADE
was	O
observed	O
during	O
and	O
immediately	O
after	O
an	O
infusion	O
of	O
arginine	B-Drug
monohydrochloride	I-Drug
in	O
two	O
patients	O
with	O
severe	O
hepatic	O
disease	O
and	O
moderate	O
renal	O
insufficiency	O
.	O

-DOCSTART-	279

CONCLUSION	O
:	O
Marked	O
visual	B-ADE
field	I-ADE
constriction	I-ADE
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	B-Drug
therapy	O
.	O

-DOCSTART-	983

Erythema	B-ADE
multiforme	I-ADE
associated	O
with	O
phenytoin	B-Drug
and	O
cranial	O
radiation	O
therapy	O
:	O
a	O
report	O
of	O
three	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	3590

We	O
report	O
two	O
cases	O
of	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
in	O
HIV-1-infected	O
patients	O
treated	O
with	O
didanosine	B-Drug
(	O
ddI	B-Drug
)	O
.	O

-DOCSTART-	1271

Mucosal	B-ADE
pigmentation	I-ADE
after	O
oral	O
lichen	O
planus	O
treatment	O
with	O
topical	O
tacrolimus	B-Drug
.	O

-DOCSTART-	2306

Divalproex	B-Drug
sodium	I-Drug
-	O
induced	O
eosinophilic	B-ADE
pleural	I-ADE
effusion	I-ADE
.	O

-DOCSTART-	4000

The	O
observation	O
of	O
cutaneous	B-ADE
vasculitis	I-ADE
during	O
administration	O
of	O
propylthiouracil	B-Drug
suggested	O
that	O
clinical	O
awareness	O
of	O
this	O
complication	O
should	O
be	O
of	O
considerable	O
importance	O
.	O

-DOCSTART-	327

We	O
propose	O
that	O
cyclophosphamide	B-Drug
be	O
added	O
to	O
the	O
list	O
of	O
exposures	O
potentially	O
associated	O
with	O
hepatic	B-ADE
angiosarcoma	I-ADE
.	O

-DOCSTART-	3666

CONCLUSIONS	O
:	O
It	O
is	O
probable	O
that	O
foscarnet	B-Drug
contributed	O
to	O
the	O
electrolyte	B-ADE
disorders	I-ADE
and	O
symptomatology	O
in	O
this	O
patient	O
.	O

-DOCSTART-	2750

Four	O
weeks	O
earlier	O
she	O
had	O
developed	O
hepatopathy	B-ADE
during	O
a	O
regimen	O
of	O
carbamazepine	B-Drug
,	O
lynestrenol	B-Drug
and	O
sodium	B-Drug
valproate	I-Drug
.	O

-DOCSTART-	3410

The	O
occurrence	O
of	O
a	O
myocardial	B-ADE
infarction	I-ADE
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	B-Drug
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factors	O
for	O
coronary	O
heart	O
disease	O
.	O

-DOCSTART-	540

We	O
presented	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
a	O
cutaneous	B-ADE
reaction	I-ADE
induced	O
by	O
captopril	B-Drug
with	O
positive	O
patch	O
test	O
.	O

-DOCSTART-	76

An	O
acute	B-ADE
ischaemic	I-ADE
event	I-ADE
associated	O
with	O
the	O
use	O
of	O
venlafaxine	B-Drug
:	O
a	O
case	O
report	O
and	O
proposed	O
pathophysiological	O
mechanisms	O
.	O

-DOCSTART-	953

This	O
case	O
and	O
a	O
review	O
of	O
the	O
literature	O
show	O
the	O
severe	O
and	O
unpredictable	O
nature	O
of	O
ethambutol	B-ADE
toxicity	I-ADE
and	O
its	O
potential	O
for	O
irreversible	O
vision	B-ADE
loss	I-ADE
despite	O
careful	O
ophthalmologic	O
monitoring	O
.	O

-DOCSTART-	506

Neutrophilic	B-ADE
dermatoses	I-ADE
in	O
two	O
children	O
with	O
idiopathic	O
neutropenia	O
:	O
association	O
with	O
granulocyte	B-Drug
colony	I-Drug
-	I-Drug
stimulating	I-Drug
factor	I-Drug
(	O
G	B-Drug
-	I-Drug
CSF	I-Drug
)	O
therapy	O
.	O

-DOCSTART-	2879

Prazosin	B-Drug
-	O
induced	O
first	O
-	O
dose	O
phenomenon	O
possibly	O
associated	O
with	O
hemorrhagic	B-ADE
stroke	I-ADE
:	O
a	O
report	O
of	O
three	O
cases	O
.	O

-DOCSTART-	194

Spinal	B-ADE
cord	I-ADE
infarction	I-ADE
during	O
use	O
of	O
zolmitriptan	B-Drug
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	19

An	O
episode	O
of	O
subacute	O
encephalopathy	B-ADE
after	O
the	O
infusion	O
of	O
a	O
moderate	O
dose	O
of	O
methotrexate	B-Drug
(	O
1500	O
mg	O
/	O
m2	O
)	O
(	O
MTX	O
)	O
is	O
reported	O
in	O
a	O
young	O
adult	O
with	O
metastastic	O
gastric	O
cancer	O
.	O

-DOCSTART-	2538

Nitrendipine	B-Drug
is	O
an	O
experimental	O
calcium	O
channel	O
blocking	O
agent	O
that	O
also	O
appears	O
to	O
cause	O
the	O
side	O
effect	O
of	O
drug	O
-	O
induced	O
gingival	B-ADE
hyperplasia	I-ADE
.	O

-DOCSTART-	2916

The	O
clinical	O
findings	O
and	O
laboratory	O
studies	O
suggested	O
an	O
autoimmune	B-ADE
cell	I-ADE
-	I-ADE
mediated	I-ADE
hypersensitivity	I-ADE
reaction	O
triggered	O
by	O
phenobarbital	B-Drug
.	O

-DOCSTART-	3664

They	O
seemed	O
to	O
involve	O
multiple	O
aetiological	O
factors	O
,	O
such	O
as	O
autoimmune	O
thyroid	O
disease	O
,	O
the	O
toxic	B-ADE
and	I-ADE
immunomodulatory	I-ADE
roles	I-ADE
of	O
lithium	B-Drug
and	O
perhaps	O
genetic	O
and	O
dietary	O
factors	O
.	O

-DOCSTART-	1891

Carbamazepine	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
is	O
a	O
rare	O
,	O
life	O
-	O
threatening	O
condition	O
.	O

-DOCSTART-	2743

Hyperkalemia	B-ADE
as	O
a	O
late	O
side	O
effect	O
of	O
prolonged	O
adrenocorticotropic	B-Drug
hormone	I-Drug
therapy	O
for	O
infantile	O
spasms	O
.	O

-DOCSTART-	3310

Bilateral	B-ADE
acoustic	I-ADE
(	I-ADE
VIII	I-ADE
)	I-ADE
nerve	I-ADE
palsy	I-ADE
in	O
this	O
patient	O
was	O
most	O
likely	O
a	O
manifestation	O
of	O
vincristine	B-Drug
neurotoxicity	B-ADE
.	O

-DOCSTART-	1198

Acute	B-ADE
hepatic	I-ADE
failure	I-ADE
is	O
a	O
rare	O
and	O
potentially	O
lethal	O
complication	O
of	O
propylthiouracil	B-Drug
(	O
PTU	B-Drug
)	O
use	O
for	O
hyperthyroidism	O
.	O

-DOCSTART-	3849

A	O
patient	O
with	O
a	O
large	O
hydatid	O
cyst	O
of	O
the	O
left	O
lobe	O
of	O
the	O
liver	O
developed	O
metabolic	B-ADE
acidosis	I-ADE
following	O
rather	O
liberal	O
use	O
of	O
cetrimide	B-Drug
-	O
chlorhexidine	B-Drug
solution	O
as	O
a	O
scolicidal	O
agent	O
.	O

-DOCSTART-	2101

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
angio	B-ADE
-	I-ADE
oedema	I-ADE
associated	O
with	O
VRC	B-Drug
.	O

-DOCSTART-	3402

Anaphylactoid	B-ADE
reactions	I-ADE
with	O
intraperitoneal	O
cisplatin	B-Drug
.	O

-DOCSTART-	3933

This	O
severe	B-ADE
illness	I-ADE
was	O
likely	O
caused	O
by	O
minocycline	B-Drug
,	O
and	O
we	O
speculate	O
that	O
minocycline	B-Drug
may	O
have	O
acted	O
as	O
a	O
superantigen	O
,	O
causing	O
lymphocyte	B-ADE
over	I-ADE
-	I-ADE
activation	I-ADE
and	O
massive	B-ADE
cytokine	I-ADE
release	I-ADE
.	O

-DOCSTART-	2963

We	O
present	O
four	O
cases	O
in	O
which	O
the	O
use	O
of	O
heparin	B-Drug
was	O
associated	O
with	O
hyperkalemia	B-ADE
and	O
discuss	O
the	O
pathophysiology	O
.	O

-DOCSTART-	3719

Azathioprine	B-Drug
-	O
induced	O
myelosuppression	B-ADE
due	O
to	O
thiopurine	O
methyltransferase	O
deficiency	O
in	O
a	O
patient	O
with	O
autoimmune	O
hepatitis	O
.	O

-DOCSTART-	2483

However	O
,	O
to	O
our	O
knowledge	O
,	O
in	O
newborns	O
there	O
have	O
been	O
no	O
reported	O
cases	O
to	O
date	O
of	O
thrombocytosis	B-ADE
induced	O
by	O
enoxaparin	B-Drug
.	O

-DOCSTART-	1518

DESIGN	O
:	O
We	O
reviewed	O
the	O
medical	O
records	O
of	O
four	O
patients	O
,	O
who	O
were	O
seen	O
by	O
us	O
between	O
July	O
2000	O
and	O
February	O
2004	O
for	O
sudden	O
onset	O
of	O
a	O
central	B-ADE
neurological	I-ADE
syndrome	I-ADE
within	O
days	O
of	O
intrathecal	O
MTX	B-Drug
.	O

-DOCSTART-	3660

The	O
potential	O
for	O
progressive	O
brain	B-ADE
injury	I-ADE
and	O
subsequent	O
disability	B-ADE
related	O
to	O
intraventricular	O
IL-2	B-Drug
therapy	O
is	O
discussed	O
.	O

-DOCSTART-	638

CONCLUSIONS	O
:	O
Peripheral	O
administration	O
of	O
low	O
-	O
dose	O
vasopressin	B-Drug
for	O
septic	O
shock	O
should	O
be	O
discouraged	O
because	O
of	O
the	O
risk	O
of	O
ischemic	B-ADE
skin	I-ADE
complications	I-ADE
.	O

-DOCSTART-	3917

DATA	O
SYNTHESIS	O
:	O
Genetic	O
deficiencies	O
in	O
DPD	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
responsible	O
for	O
5-FU	B-Drug
catabolism	O
,	O
may	O
occur	O
in	O
3	O
%	O
or	O
more	O
of	O
patients	O
with	O
cancer	O
putting	O
them	O
at	O
increased	O
risk	O
for	O
unusually	O
severe	O
adverse	O
reactions	O
(	O
e.g.	O
,	O
diarrhea	B-ADE
,	O
stomatitis	B-ADE
,	O
mucositis	B-ADE
,	O
myelosuppression	B-ADE
,	O
neurotoxicity	B-ADE
)	O
to	O
standard	O
doses	O
of	O
5-FU	B-Drug
.	O

-DOCSTART-	2148

Although	O
it	O
is	O
difficult	O
to	O
solely	O
attribute	O
intratumoral	B-ADE
hemorrhage	I-ADE
to	O
aspirin	B-Drug
,	O
we	O
have	O
to	O
be	O
careful	O
when	O
prescribing	O
aspirin	O
for	O
patients	O
who	O
have	O
asymptomatic	O
meningioma	O
.	O

-DOCSTART-	2401

He	O
had	O
hypokalemia	B-ADE
(	O
K	O
2.3	O
mmol	O
/	O
L	O
)	O
induced	O
by	O
licorice	B-Drug
and	O
also	O
had	O
received	O
disopyramide	O
for	O
arrhythmia	O
,	O
bicalutamide	O
for	O
prostate	O
cancer	O
,	O
and	O
silodosin	O
for	O
prostate	O
hypertrophy	O
.	O

-DOCSTART-	1546

Administration	O
of	O
sumatriptan	B-Drug
in	O
subarachnoid	O
haemorrhage	O
(	O
SAH	O
)	O
patients	O
,	O
misdiagnosed	O
as	O
migraine	O
patients	O
,	O
may	O
induce	O
symptomatic	B-ADE
cerebral	I-ADE
vasospasm	I-ADE
with	O
potentially	O
dangerous	O
consequences	O
.	O

-DOCSTART-	3394

We	O
report	O
a	O
16-year	O
-	O
old	O
male	O
who	O
developed	O
nephrotic	B-ADE
syndrome	I-ADE
related	O
to	O
membranous	O
glomerulopathy	O
with	O
clinical	O
and	O
serological	O
evidence	O
of	O
systemic	B-ADE
lupus	I-ADE
erythematosus	I-ADE
after	O
treatment	O
with	O
griseofulvin	B-Drug
.	O

-DOCSTART-	2666

This	O
report	O
describes	O
two	O
patients	O
who	O
developed	O
acute	B-ADE
myelocytic	I-ADE
leukemia	I-ADE
only	O
after	O
exposure	O
to	O
cyclophosphamide	B-Drug
,	O
methotrexate	B-Drug
,	O
and	O
5-fluorouracil	B-Drug
adjuvant	O
therapy	O
.	O

-DOCSTART-	3701

We	O
report	O
one	O
case	O
of	O
non	B-ADE
-	I-ADE
Hodgkin	I-ADE
lymphoma	I-ADE
in	O
a	O
patient	O
,	O
with	O
a	O
30-year	O
history	O
of	O
rheumatoid	O
arthritis	O
,	O
taking	O
low	O
dose	O
methotrexate	B-Drug
weekly	O
over	O
a	O
10-month	O
period	O
.	O

-DOCSTART-	2009

Hyponatraemia	B-ADE
during	O
low	O
-	O
dose	O
carbamazepine	B-Drug
therapy	O
.	O

-DOCSTART-	4198

A	O
65-year	O
-	O
old	O
woman	O
with	O
angina	O
pectoris	O
presented	O
with	O
syncope	B-ADE
after	O
sublingual	O
ingestion	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
(	O
5	O
mg	O
)	O
.	O

-DOCSTART-	676

PURPOSE	O
:	O
To	O
describe	O
the	O
clinical	O
and	O
electrophysiological	O
findings	O
in	O
a	O
young	O
boy	O
with	O
decreased	B-ADE
vision	I-ADE
possibly	O
due	O
to	O
retinal	B-ADE
damage	I-ADE
by	O
rifabutin	B-Drug
.	O

-DOCSTART-	2166

After	O
the	O
first	O
oral	O
dose	O
of	O
propranolol	B-Drug
,	O
syncope	B-ADE
developed	O
together	O
with	O
atrioventricular	B-ADE
block	I-ADE
.	O

-DOCSTART-	946

Neurotoxicity	B-ADE
of	O
intrathecal	O
methotrexate	B-Drug
:	O
MR	O
imaging	O
findings	O
.	O

-DOCSTART-	1034

RESULTS	O
:	O
A	O
patient	O
developed	O
a	O
bilaterally	B-ADE
symmetric	I-ADE
bull's	I-ADE
-	I-ADE
eye	I-ADE
maculopathy	I-ADE
45	O
years	O
after	O
taking	O
quinacrine	B-Drug
for	O
18	O
months	O
as	O
prophylaxis	O
against	O
malaria	O
.	O

-DOCSTART-	1381

ADR	O
induced	O
by	O
drug	O
treatment	O
can	O
be	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
antipsychotic	O
drugs	O
and	O
other	O
drugs	O
;	O
however	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
lamivudine	B-Drug
-	O
induced	O
ADR	B-ADE
in	O
the	O
English	O
literature	O
.	O

-DOCSTART-	3375

Monoclonal	B-ADE
gammopathy	I-ADE
and	O
subsequent	O
multiple	B-ADE
myeloma	I-ADE
in	O
a	O
patient	O
on	O
chronic	O
diphenylhydantoin	B-Drug
therapy	O
.	O

-DOCSTART-	2547

Acute	B-ADE
coronary	I-ADE
events	I-ADE
following	O
cisplatin	B-Drug
-	O
based	O
chemotherapy	O
.	O

-DOCSTART-	4066

Ifosfamide	B-Drug
-	O
associated	O
neurotoxicity	B-ADE
was	O
noted	O
within	O
hours	O
of	O
drug	O
administration	O
and	O
improved	O
rapidly	O
following	O
hemodialysis	O
.	O

-DOCSTART-	764

Successful	O
treatment	O
with	O
carbimazole	O
of	O
a	O
hyperthyroid	O
pregnancy	O
with	O
hepatic	B-ADE
impairment	I-ADE
after	O
propylthiouracil	B-Drug
administration	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3005

Two	O
other	O
patients	O
who	O
did	O
not	O
receive	O
prochlorperazine	O
,	O
developed	O
retinal	B-ADE
problems	I-ADE
which	O
later	O
improved	O
,	O
one	O
after	O
only	O
15	O
g	O
of	O
desferrioxamine	B-Drug
.	O

-DOCSTART-	1040

Central	O
nervous	O
system	O
effects	O
secondary	O
to	O
ciprofloxacin	B-Drug
treatment	O
are	O
uncommon	O
and	O
usually	O
consist	O
only	O
of	O
minor	B-ADE
dizziness	I-ADE
or	O
mild	B-ADE
headache	I-ADE
,	O
although	O
rare	O
occurrences	O
of	O
seizures	B-ADE
and	O
hallucinations	B-ADE
have	O
been	O
reported	O
.	O

-DOCSTART-	2626

Five	O
patients	O
receiving	O
fluoxetine	B-Drug
for	O
the	O
treatment	O
of	O
obsessive	O
compulsive	O
disorder	O
or	O
major	O
depression	O
developed	O
akathisia	B-ADE
.	O

-DOCSTART-	1818

This	O
is	O
a	O
report	O
of	O
a	O
renal	O
transplant	O
patient	O
with	O
Pneumocystis	O
pneumonia	O
who	O
developed	O
chemical	B-ADE
cellulitis	I-ADE
and	O
ulceration	B-ADE
following	O
the	O
extravasation	O
of	O
intravenous	O
pentamidine	B-Drug
into	O
the	O
soft	O
tissues	O
of	O
the	O
left	O
hand	O
and	O
forearm	O
.	O

-DOCSTART-	3886

Painful	B-ADE
erosion	I-ADE
of	I-ADE
psoriatic	I-ADE
plaques	I-ADE
is	O
a	O
less	O
common	O
sign	O
of	O
methotrexate	B-Drug
toxicity	I-ADE
that	O
may	O
precede	O
evidence	O
of	O
bone	B-ADE
marrow	I-ADE
suppression	I-ADE
.	O

-DOCSTART-	2500

Severe	B-ADE
aphthous	I-ADE
stomatitis	I-ADE
associated	O
with	O
oral	O
calcineurin	B-Drug
and	O
mTOR	O
inhibitors	O
.	O

-DOCSTART-	11

We	O
report	O
a	O
case	O
of	O
reversible	O
encephalopathy	B-ADE
syndrome	I-ADE
in	O
a	O
16-year	O
-	O
old	O
girl	O
with	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
who	O
is	O
undergoing	O
during	O
consolidation	O
chemotherapy	O
composed	O
of	O
BH	B-Drug
-	I-Drug
AC	I-Drug
(	O
N4-behenoyl-1-beta	O
-	O
D	O
-	O
arabinofuranosyl	O
cytosine	O
)	O
and	O
idarubicin	B-Drug
.	O

-DOCSTART-	4153

We	O
describe	O
a	O
patient	O
with	O
M4	O
AML	O
treated	O
with	O
standard	O
chemotherapy	O
followed	O
by	O
G	B-Drug
-	I-Drug
CSF	I-Drug
who	O
developed	O
marked	O
monocytosis	B-ADE
on	O
day	O
8	O
of	O
G	B-Drug
-	I-Drug
CSF	I-Drug
therapy	O
.	O

-DOCSTART-	2522

Concomitant	O
irradiation	O
apparently	O
enhanced	O
the	O
skin	B-ADE
toxicity	I-ADE
of	O
aminoglutethimide	B-Drug
or	O
possibly	O
aminoglutethimide	O
had	O
a	O
radiosensitizing	O
role	O
in	O
this	O
patient	O
.	O

-DOCSTART-	3422

Comparable	O
adverse	O
effects	O
,	O
such	O
as	O
disorientation	B-ADE
and	O
temporary	B-ADE
amnesia	I-ADE
,	O
have	O
been	O
reported	O
in	O
patients	O
in	O
the	O
analogous	O
agent	O
,	O
propranolol	B-Drug
.	O

-DOCSTART-	1881

An	O
apparent	O
link	O
is	O
described	O
between	O
the	O
use	O
of	O
MMF	B-Drug
with	O
prednisone	B-Drug
to	O
treat	O
pemphigus	O
vulgaris	O
and	O
the	O
development	O
of	O
red	B-ADE
blood	I-ADE
cell	I-ADE
anemia	I-ADE
.	O

-DOCSTART-	3624

BACKGROUND	O
:	O
Fluoxetine	B-Drug
,	O
a	O
highly	O
specific	O
serotonin	O
reuptake	O
inhibitor	O
,	O
has	O
been	O
reported	O
to	O
cause	O
sexual	B-ADE
dysfunction	I-ADE
in	O
a	O
minority	O
of	O
patients	O
.	O

-DOCSTART-	463

Didanosine	B-Drug
also	O
has	O
a	O
potential	O
for	O
inducing	O
seizures	B-ADE
.	O

-DOCSTART-	763

Antithyroid	O
treatment	O
with	O
propylthiouracil	B-Drug
(	O
PTU	B-Drug
)	O
resulted	O
in	O
elevated	B-ADE
hepatic	I-ADE
enzymes	I-ADE
and	O
after	O
the	O
12th	O
week	O
of	O
pregnancy	O
treatment	O
was	O
changed	O
to	O
carbimazole	O
(	O
CBZ	O
)	O
.	O

-DOCSTART-	1468

Penicillin	B-Drug
-	O
induced	O
Jarisch	B-ADE
-	I-ADE
Herxheimer	I-ADE
reaction	I-ADE
.	O

-DOCSTART-	863

Argatroban	O
for	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
in	O
hepato	O
-	O
renal	O
failure	O
and	O
CVVHD	O
.	O

-DOCSTART-	3995

Relapse	B-ADE
in	I-ADE
the	I-ADE
external	I-ADE
auditory	I-ADE
canal	I-ADE
of	I-ADE
acute	I-ADE
promyelocytic	I-ADE
leukemia	I-ADE
after	O
treatment	O
with	O
all	B-Drug
-	I-Drug
trans	I-Drug
retinoic	I-Drug
acid	I-Drug
.	O

-DOCSTART-	3953

She	O
continued	O
taking	O
verapamil	O
for	O
6	O
months	O
,	O
then	O
,	O
on	O
her	O
own	O
,	O
stopped	O
all	O
medications	O
including	O
the	O
sustained	O
-	O
release	O
verapamil	B-Drug
,	O
and	O
her	O
asthma	B-ADE
symptoms	O
disappeared	O
.	O

-DOCSTART-	2186

Radiologic	O
recognition	O
of	O
adriamycin	B-Drug
cardiotoxicity	B-ADE
.	O

-DOCSTART-	4035

Danazol	B-Drug
induced	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	1529

We	O
report	O
a	O
case	O
with	O
chronic	O
hepatitis	O
C	O
(	O
CHC	O
)	O
who	O
developed	O
sarcoidosis	B-ADE
after	O
the	O
treatment	O
by	O
interferon	B-Drug
alpha	I-Drug
and	O
ribavirin	B-Drug
.	O

-DOCSTART-	3732

Supravenous	B-ADE
hyperpigmentation	I-ADE
in	O
association	O
with	O
CHOP	B-Drug
chemotherapy	O
of	O
a	O
CD30	O
(	O
Ki-1	O
)	O
-	O
positive	O
anaplastic	O
large	O
-	O
cell	O
lymphoma	O
.	O

-DOCSTART-	3363

However	O
,	O
we	O
have	O
recently	O
had	O
four	O
cases	O
of	O
clofibrate	B-Drug
-	O
induced	O
myopathy	B-ADE
in	O
patients	O
with	O
diabetes	O
insipidus	O
due	O
to	O
hypothalamic	O
lesions	O
.	O

-DOCSTART-	4017

Hypersensitivity	B-ADE
reactions	I-ADE
to	O
cisplatin	B-Drug
following	O
multiple	O
uncomplicated	O
courses	O
:	O
a	O
report	O
on	O
two	O
cases	O
.	O

-DOCSTART-	3203

No	O
other	O
endogenous	O
or	O
exogenous	O
cause	O
for	O
the	O
gynecomastia	B-ADE
could	O
be	O
found	O
except	O
for	O
the	O
theophylline	B-Drug
.	O

-DOCSTART-	1464

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
insulin	B-Drug
-	O
induced	O
lipohypertrophy	B-ADE
with	O
detailed	O
histological	O
examinations	O
.	O

-DOCSTART-	2096

Spontaneous	B-ADE
nasal	I-ADE
septal	I-ADE
perforation	I-ADE
with	O
antiangiogenic	O
bevacizumab	B-Drug
therapy	O
.	O

-DOCSTART-	285

Treatment	O
of	O
chronic	O
hepatitis	O
C	O
with	O
interferon	B-Drug
alpha	I-Drug
(	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
)	O
is	O
relatively	O
contraindicated	O
in	O
patients	O
with	O
psychiatric	O
disorders	O
because	O
of	O
possible	O
severe	O
psychiatric	B-ADE
side	I-ADE
effects	I-ADE
.	O

-DOCSTART-	1082

Acute	B-ADE
dystonia	I-ADE
during	O
pegylated	B-Drug
interferon	I-Drug
alpha	I-Drug
therapy	O
in	O
a	O
case	O
with	O
chronic	O
hepatitis	O
B	O
infection	O
.	O

-DOCSTART-	3279

Flucytosine	B-Drug
-	O
associated	O
diarrhea	B-ADE
has	O
been	O
previously	O
described	O
in	O
6%-10	O
%	O
of	O
patients	O
receiving	O
the	O
drug	O
.	O

-DOCSTART-	1089

We	O
describe	O
a	O
heroin	O
abuser	O
in	O
whom	O
clinical	O
and	O
laboratory	O
manifestations	O
of	O
acute	B-ADE
hepatitis	I-ADE
B	I-ADE
and	I-ADE
C	I-ADE
appeared	O
a	O
few	O
days	O
after	O
the	O
insertion	O
of	O
a	O
subcutaneous	O
naltrexone	B-Drug
implant	O
.	O

-DOCSTART-	2811

Anhedonic	B-ADE
ejaculation	I-ADE
with	O
desipramine	B-Drug
.	O

-DOCSTART-	1652

Olanzapine	B-Drug
-	O
associated	O
neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	516

Reversal	O
of	O
severe	O
methanol	B-Drug
-	O
induced	O
visual	B-ADE
impairment	I-ADE
:	O
no	O
evidence	O
of	O
retinal	O
toxicity	O
due	O
to	O
fomepizole	O
.	O

-DOCSTART-	3362

Clofibrate	B-Drug
-	O
induced	O
myopathy	B-ADE
in	O
patients	O
with	O
diabetes	O
insipidus	O
.	O

-DOCSTART-	906

Dilated	B-ADE
cardiomyopathy	I-ADE
associated	O
with	O
chronic	O
overuse	O
of	O
an	O
adrenaline	B-Drug
inhaler	O
.	O

-DOCSTART-	4086

CONCLUSIONS	O
:	O
Hypersensitivity	B-ADE
reactions	I-ADE
to	O
cyclosporine	B-Drug
are	O
due	O
to	O
Cremophor	B-Drug
EL	I-Drug
.	O

-DOCSTART-	78

This	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
association	O
between	O
an	O
acute	B-ADE
cardiovascular	I-ADE
event	I-ADE
and	O
venlafaxine	B-Drug
.	O

-DOCSTART-	3526

Temporary	B-ADE
neurologic	I-ADE
abnormalities	I-ADE
were	O
observed	O
in	O
one	O
out	O
of	O
23	O
patients	O
undergoing	O
chemotherapy	O
with	O
high	O
-	O
dose	O
methotrexate	B-Drug
(	O
HD	O
-	O
MTX	O
)	O
for	O
osteogenic	O
sarcoma	O
.	O

-DOCSTART-	1462

Insulin	B-Drug
-	O
induced	O
lipohypertrophy	B-ADE
:	O
report	O
of	O
a	O
case	O
with	O
histopathology	O
.	O

-DOCSTART-	877

Anaphylaxis	B-ADE
after	O
the	O
injection	O
of	O
chymopapain	B-Drug
occurs	O
in	O
about	O
1	O
%	O
of	O
such	O
cases	O
.	O

-DOCSTART-	140

Salicylate	O
intoxication	B-ADE
was	O
excluded	O
,	O
and	O
theophylline	B-Drug
was	O
finally	O
incriminated	O
.	O

-DOCSTART-	3830

Less	O
common	O
adverse	O
events	O
to	O
dapsone	B-Drug
include	O
the	O
idiosyncratic	O
reactions	O
of	O
leukopenia	B-ADE
and	O
agranulocytosis	B-ADE
,	O
cutaneous	B-ADE
eruptions	I-ADE
,	O
peripheral	B-ADE
neuropathy	I-ADE
,	O
psychosis	B-ADE
,	O
toxic	B-ADE
hepatitis	I-ADE
,	O
cholestatic	B-ADE
jaundice	I-ADE
,	O
nephrotic	B-ADE
syndrome	I-ADE
,	O
renal	B-ADE
papillary	I-ADE
necrosis	I-ADE
,	O
severe	B-ADE
hypoalbuminemia	I-ADE
without	I-ADE
proteinuria	I-ADE
,	O
an	B-ADE
infectious	I-ADE
mononucleosis	I-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
,	O
and	O
minor	B-ADE
neurological	I-ADE
and	I-ADE
gastrointestinal	I-ADE
complaints	I-ADE
.	O

-DOCSTART-	1257

CONCLUSION	O
:	O
This	O
rare	O
case	O
of	O
PTU	B-Drug
-	O
induced	O
ANCA	B-ADE
-	I-ADE
associated	I-ADE
vasculitis	I-ADE
manifested	O
with	O
ototoxicity	B-ADE
in	O
combination	O
with	O
systemic	O
involvement	O
.	O

-DOCSTART-	1985

Upper	B-ADE
gastrointestinal	I-ADE
haemorrhage	I-ADE
is	O
a	O
serious	O
complication	O
of	O
aspirin	B-Drug
and	O
clopidogrel	B-Drug
(	O
dual	O
)	O
anti	O
-	O
platelet	O
therapy	O
with	O
a	O
high	O
morbidity	O
and	O
mortality	O
.	O

-DOCSTART-	2636

Peculiar	O
nail	B-ADE
-	I-ADE
changes	I-ADE
in	O
a	O
70-year	O
-	O
old	O
woman	O
with	O
rheumatoid	O
arthritis	O
occurring	O
after	O
approximately	O
1	O
year	O
of	O
penicillamine	B-Drug
treatment	O
are	O
described	O
.	O

-DOCSTART-	1675

We	O
describe	O
a	O
case	O
of	O
an	O
NHL	O
patient	O
who	O
received	O
rituximab	B-Drug
and	O
developed	O
symptomatic	O
,	O
biopsy	O
-	O
proven	O
multinodular	O
bronchiolitis	B-ADE
obliterans	I-ADE
with	I-ADE
organizing	I-ADE
pneumonia	I-ADE
(	O
BOOP	O
)	O
.	O

-DOCSTART-	3510

This	O
is	O
a	O
report	O
of	O
a	O
case	O
of	O
anuric	B-ADE
ARF	I-ADE
after	O
high	O
-	O
dose	O
mannitol	B-Drug
infusion	O
for	O
treatment	O
of	O
narrow	O
-	O
angle	O
glaucoma	O
that	O
readily	O
responded	O
to	O
acute	O
hemodialysis	O
.	O

-DOCSTART-	3018

The	O
toxic	O
effects	O
of	O
methotrexate	B-Drug
included	O
elevated	B-ADE
liver	I-ADE
transaminases	I-ADE
(	O
3/4	O
)	O
,	O
nausea	B-ADE
(	O
2/4	O
)	O
,	O
abdominal	B-ADE
pain	I-ADE
(	O
2/4	O
)	O
,	O
bone	B-ADE
pain	I-ADE
(	O
2/4	O
)	O
,	O
mild	B-ADE
neutropenia	I-ADE
(	O
1/4	O
)	O
,	O
and	O
mild	B-ADE
pruritus	I-ADE
(	O
1/4	O
)	O
.	O

-DOCSTART-	3728

However	O
,	O
in	O
1993	O
,	O
a	O
clinical	O
study	O
involving	O
400	O
patients	O
on	O
the	O
Thai	O
-	O
Burmese	O
border	O
revealed	O
cardiac	B-ADE
effects	I-ADE
of	O
antimalarial	O
treatment	O
with	O
halofantrine	B-Drug
,	O
including	O
one	O
sudden	B-ADE
death	I-ADE
after	O
the	O
treatment	O
.	O

-DOCSTART-	532

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
serotonin	B-ADE
syndrome	I-ADE
with	O
serious	O
extrapyramidal	B-ADE
movement	I-ADE
disorders	I-ADE
occurring	O
when	O
metoclopramide	B-Drug
was	O
coadministered	O
with	O
sertraline	B-Drug
or	O
venlafaxine	B-Drug
.	O

-DOCSTART-	4268

Lithium	B-Drug
treatment	O
was	O
terminated	O
in	O
1975	O
because	O
of	O
lithium	B-Drug
intoxication	I-ADE
with	O
a	O
diabetes	B-ADE
insipidus	I-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	458

We	O
describe	O
a	O
patient	O
who	O
experienced	O
a	O
lichenoid	B-ADE
eruption	I-ADE
after	O
the	O
initiation	O
of	O
salsalate	B-Drug
for	O
relief	O
of	O
arthritic	O
pain	O
.	O

-DOCSTART-	2514

Splenic	B-ADE
hemorrhage	I-ADE
:	O
a	O
complication	O
of	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
treatment	O
.	O

-DOCSTART-	2958

The	O
risk	O
of	O
cardiac	B-ADE
decompensation	I-ADE
in	O
infants	O
with	O
supraventricular	O
tachycardia	O
and	O
congestive	O
cardiac	O
failure	O
should	O
be	O
kept	O
in	O
mind	O
prior	O
to	O
administration	O
of	O
verapamil	B-Drug
.	O

-DOCSTART-	796

We	O
describe	O
a	O
patient	O
who	O
developed	O
acute	B-ADE
cerebellar	I-ADE
syndrome	I-ADE
after	O
prophylactic	O
intrathecal	O
methotrexate	B-Drug
administration	O
and	O
recovered	O
spontaneously	O
.	O

-DOCSTART-	3205

Parenteral	O
-	O
verapamil	B-Drug
-	O
induced	O
sustained	B-ADE
hypotension	I-ADE
.	O

-DOCSTART-	3528

Transient	B-ADE
neurological	I-ADE
disturbances	I-ADE
induced	O
by	O
the	O
chemotherapy	O
of	O
high	O
-	O
dose	O
methotrexate	B-Drug
for	O
osteogenic	O
sarcoma	O
.	O

-DOCSTART-	1700

Late	O
lethal	O
hepatitis	B-ADE
B	I-ADE
virus	I-ADE
reactivation	I-ADE
after	O
rituximab	B-Drug
treatment	O
of	O
low	O
-	O
grade	O
cutaneous	O
B	O
-	O
cell	O
lymphoma	O
.	O

-DOCSTART-	2217

A	O
52	O
year	O
-	O
old	O
male	O
patient	O
diagnosed	O
of	O
ankylosing	O
spondylitis	O
presented	O
with	O
an	O
iron	B-ADE
deficiency	I-ADE
anemia	I-ADE
after	O
a	O
ten	O
-	O
month	O
treatment	O
of	O
methotrexate	B-Drug
.	O

-DOCSTART-	182

This	O
case	O
report	O
illustrates	O
the	O
use	O
of	O
continuous	O
high	O
-	O
dose	O
intracoronary	O
nitroglycerin	O
infusion	O
through	O
a	O
6	O
French	O
coronary	O
guiding	O
catheter	O
in	O
the	O
treatment	O
of	O
a	O
patient	O
with	O
cocaine	B-Drug
-	O
induced	O
refractory	B-ADE
coronary	I-ADE
vasospasm	I-ADE
.	O

-DOCSTART-	2964

While	O
most	O
physicians	O
are	O
aware	O
of	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
and	O
skin	B-ADE
necrosis	I-ADE
,	O
the	O
association	O
of	O
heparin	B-Drug
and	O
hyperkalemia	B-ADE
is	O
less	O
well	O
recognized	O
.	O

-DOCSTART-	2191

Although	O
heparin	O
-	O
dependent	O
antibodies	O
(	O
HDAs	O
)	O
typically	O
manifest	O
with	O
thrombocytopenia	O
as	O
in	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
(	O
HIT	O
)	O
,	O
they	O
may	O
also	O
manifest	O
with	O
preserved	O
platelet	O
counts	O
.	O

-DOCSTART-	2932

Antibiotic	O
-	O
associated	O
colitis	B-ADE
(	O
pseudomembranous	B-ADE
colitis	I-ADE
)	O
developed	O
in	O
four	O
patients	O
with	O
spinal	O
cord	O
injury	O
and	O
taking	O
oral	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
.	O

-DOCSTART-	2074

The	O
fourth	O
patient	O
showed	O
RLS	B-ADE
symptoms	I-ADE
that	O
were	O
initially	O
caused	O
by	O
a	O
20-mg	O
daily	O
olanzapine	B-Drug
dosage	O
and	O
were	O
later	O
mitigated	O
when	O
olanzapine	O
was	O
reduced	O
and	O
ropinirole	O
was	O
administered	O
.	O

-DOCSTART-	3541

We	O
describe	O
a	O
patient	O
with	O
a	O
liver	B-ADE
abscess	I-ADE
due	O
to	O
Entamoeba	O
histolytica	O
,	O
in	O
whom	O
metronidazole	B-Drug
therapy	O
(	O
total	O
dose	O
,	O
21	O
g	O
over	O
14	O
days	O
)	O
was	O
complicated	O
by	O
reversible	B-ADE
deafness	I-ADE
,	O
tinnitus	B-ADE
,	O
and	O
ataxia	B-ADE
and	O
who	O
relapsed	O
5	O
months	O
later	O
with	O
a	O
splenic	B-ADE
abscess	I-ADE
.	O

-DOCSTART-	269

Patients	O
treated	O
with	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
may	O
present	O
with	O
hemorrhagic	B-ADE
and	O
thrombotic	B-ADE
cerebrovascular	I-ADE
events	I-ADE
.	O

-DOCSTART-	2393

In	O
one	O
patient	O
the	O
vasculitis	B-ADE
resolved	O
after	O
termination	O
of	O
the	O
ciprofloxacin	B-Drug
therapy	O
;	O
in	O
the	O
other	O
patient	O
the	O
ciprofloxacin	B-Drug
-	O
induced	O
hemorrhagic	B-ADE
vasculitis	I-ADE
was	O
superimposed	O
on	O
a	O
severe	B-ADE
forefoot	I-ADE
infection	I-ADE
,	O
leading	O
to	O
progressive	B-ADE
gangrene	I-ADE
and	O
a	O
below	B-ADE
-	I-ADE
knee	I-ADE
amputation	I-ADE
.	O

-DOCSTART-	4097

Development	O
of	O
essential	O
thrombocythemia	B-ADE
in	O
a	O
patient	O
treated	O
with	O
interferon	B-Drug
alfa	I-Drug
and	O
pentostatin	B-Drug
for	O
hairy	O
cell	O
leukemia	O
.	O

-DOCSTART-	2726

Cataracts	B-ADE
induced	O
by	O
intermittent	O
Decadron	B-Drug
used	O
as	O
an	O
antiemetic	O
.	O

-DOCSTART-	3364

Physicians	O
should	O
therefore	O
be	O
aware	O
of	O
its	O
occurrence	O
and	O
carefully	O
monitor	O
serum	O
levels	O
of	O
CPK	O
,	O
GOT	O
and	O
GPT	O
during	O
the	O
treatment	O
of	O
diabetes	O
insipidus	O
with	O
clofibrate	B-Drug
,	O
especially	O
in	O
patients	O
with	O
associated	O
hypothyroidism	O
,	O
latent	O
or	O
overt	O
,	O
which	O
possibly	O
favors	O
the	O
development	O
of	O
myopathy	B-ADE
.	O

-DOCSTART-	2237

Two	O
patients	O
who	O
developed	O
decreased	B-ADE
visual	I-ADE
acuity	I-ADE
after	O
several	O
months	O
of	O
ethambutol	B-Drug
treatment	O
for	O
Mycobacterium	O
avium	O
-	O
intracellulare	O
infection	O
had	O
bitemporal	B-ADE
visual	I-ADE
field	I-ADE
defects	I-ADE
that	O
suggested	O
optic	O
chiasm	O
damage	O
.	O

-DOCSTART-	4044

Therefore	O
,	O
we	O
diagnosed	O
her	O
eruption	B-ADE
as	O
contact	B-ADE
dermatitis	I-ADE
due	O
to	O
sodium	B-Drug
bisulfite	I-Drug
.	O

-DOCSTART-	323

There	O
is	O
evidence	O
that	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
,	O
losartan	B-Drug
,	O
increases	B-ADE
urate	I-ADE
excretion	I-ADE
by	O
reducing	O
reabsorption	O
of	O
urate	O
in	O
the	O
renal	O
proximal	O
tubule	O
.	O

-DOCSTART-	2991

A	O
65-year	O
-	O
old	O
woman	O
with	O
bipolar	O
disorder	O
and	O
complicated	O
cardiovascular	O
disease	O
who	O
was	O
on	O
maintenance	O
lithium	B-Drug
therapy	O
developed	O
a	O
movement	B-ADE
disorder	I-ADE
following	O
high	O
doses	O
of	O
trazodone	B-Drug
for	O
treatment	O
of	O
an	O
acute	O
depression	O
.	O

-DOCSTART-	4087

Fortunately	O
,	O
a	O
hypersensitivity	B-ADE
reaction	I-ADE
to	O
one	O
formulation	O
of	O
cyclosporine	B-Drug
does	O
not	O
preclude	O
use	O
of	O
a	O
different	O
formulation	O
.	O

-DOCSTART-	2955

Chronic	B-ADE
photosensitivity	I-ADE
associated	O
with	O
hydrochlorothiazide	B-Drug
ingestion	O
occurred	O
in	O
four	O
patients	O
.	O

-DOCSTART-	3494

Five	O
patients	O
are	O
described	O
in	O
whom	O
only	O
gentamicin	B-Drug
sulfate	I-Drug
appeared	O
responsible	O
for	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	3166

Cholestyramine	B-Drug
induced	O
hyperchloremic	B-ADE
metabolic	I-ADE
acidosis	I-ADE
.	O

-DOCSTART-	4063

Agranulocytosis	B-ADE
associated	O
with	O
ticlopidine	B-Drug
:	O
a	O
possible	O
benefit	O
with	O
filgastim	O
.	O

-DOCSTART-	1703

This	O
is	O
a	O
case	O
report	O
of	O
fatal	O
cryptococcal	B-ADE
meningitis	I-ADE
in	O
a	O
child	O
with	O
systemic	O
lupus	O
erythematosus	O
being	O
treated	O
with	O
prednisolone	B-Drug
and	O
azathioprine	B-Drug
.	O

-DOCSTART-	2791

This	O
confirmed	O
the	O
history	O
of	O
captopril	B-Drug
-	O
related	O
asthma	B-ADE
.	O

-DOCSTART-	882

Carbamazepine	B-Drug
-	O
induced	O
systemic	B-ADE
lupus	I-ADE
erythematosus	I-ADE
-	I-ADE
like	I-ADE
disease	I-ADE
.	O

-DOCSTART-	1399

The	O
patient	O
continued	O
to	O
have	O
fever	B-ADE
and	O
autonomic	B-ADE
instability	I-ADE
without	O
evidence	O
of	O
infection	O
which	O
entirely	O
resolved	O
within	O
24	O
hours	O
of	O
reinstitution	O
of	O
full	O
preadmission	O
dosing	O
of	O
oral	O
baclofen	B-Drug
.	O

-DOCSTART-	739

Patients	O
with	O
lymphoblastic	O
lymphoma	O
who	O
had	O
treatment	O
with	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
and	O
steroid	O
are	O
predisposed	O
to	O
the	O
development	O
of	O
cortical	B-ADE
venous	I-ADE
thrombosis	I-ADE
and	O
may	O
have	O
this	O
syndrome	O
in	O
addition	O
to	O
a	O
dural	B-ADE
puncture	I-ADE
headache	I-ADE
.	O

-DOCSTART-	3798

Six	O
days	O
after	O
starting	O
acyclovir	B-Drug
she	O
exhibited	O
signs	O
of	O
lithium	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	755

These	O
observations	O
indicate	O
that	O
submassive	B-ADE
hepatic	I-ADE
necrosis	I-ADE
may	O
result	O
from	O
treatment	O
with	O
propylthiouracil	B-Drug
and	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
sensitization	O
mechanisms	O
may	O
be	O
responsible	O
for	O
the	O
hepatic	B-ADE
injury	I-ADE
induced	O
by	O
this	O
drug	O
.	O

-DOCSTART-	1566

This	O
case	O
underscores	O
problems	O
in	O
clinical	O
management	O
with	O
sulfadiazine	B-Drug
hypersensitivity	B-ADE
,	O
potential	O
immunosuppression	O
from	O
corticosteroids	O
and	O
selection	O
of	O
medications	O
for	O
recurrences	O
of	O
toxoplasmic	O
chorioretinitis	O
.	O

-DOCSTART-	2024

PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
bilateral	B-ADE
anterior	I-ADE
uveitis	I-ADE
associated	O
with	O
ovulation	O
induction	O
therapy	O
using	O
clomiphene	B-Drug
citrate	I-Drug
.	O

-DOCSTART-	621

Severe	O
erythroderma	B-ADE
as	O
a	O
complication	O
of	O
continuous	O
epoprostenol	B-Drug
therapy	O
.	O

-DOCSTART-	1562

We	O
describe	O
a	O
patient	O
who	O
developed	O
granulocytopenia	B-ADE
and	O
fever	O
after	O
taking	O
dipyrone	B-Drug
and	O
discuss	O
the	O
available	O
literature	O
.	O

-DOCSTART-	840

Acute	B-ADE
abdomen	I-ADE
due	O
to	O
endometriosis	B-ADE
in	O
a	O
premenopausal	O
woman	O
taking	O
tamoxifen	B-Drug
.	O

-DOCSTART-	851

Obsessive	B-ADE
-	I-ADE
compulsive	I-ADE
symptoms	I-ADE
suddenly	O
emerged	O
10	O
days	O
after	O
starting	O
risperidone	B-Drug
and	O
resolved	O
within	O
3	O
days	O
of	O
discontinuation	O
.	O

-DOCSTART-	3063

Reversal	O
of	O
ergotamine	B-Drug
-	O
induced	O
arteriospasm	B-ADE
by	O
mechanical	O
intra	O
-	O
arterial	O
dilatation	O
.	O

-DOCSTART-	411

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
pancytopenia	B-ADE
due	O
to	O
MMI	B-Drug
,	O
where	O
the	O
usual	O
hypoplasia	O
found	O
is	O
replaced	O
by	O
massive	B-ADE
plasmocytosis	I-ADE
.	O

